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Perfluorooctanoic acid (PFOA) is a synthetic chemical used in polyfluormer production. 
It is a widespread environmental contaminant and is known to induce developmental toxicity in 
rodent models. As several related compounds also induce developmental cardiotoxicity in  avian 
models, a series of experiments were carried out in chicken embryos and hatchling chickens to 
assess the effects of PFOA on developing hearts and to explore underlying mechanisms. 
Histology was used to assess late stage embryo hearts and echocardiography was used to assess 
morphological and functional parameters of hearts in living one-day-old hatchlings. Hearts of 
exposed embryos had a thinned right ventricular wall and multiple morphological and functional 
changes were detected in the left ventricles of exposed hatchlings. As PFOA is known to activate 
the peroxisome proliferator activated receptor α (PPARα) in rodent models, the PPARα agonist 
WY 14,643 was used to assess the role of PPARα in PFOA-induced developmental 
cardiotoxicity. Real-time polymerase chain reaction (PCR) and western blot were used to assess 
hearts of early stage embryos for expression of genes related to heart development. WY 14,643 
partially mimicked the morphological and functional effects of PFOA only in the left ventricle of 
hearts of hatchling chickens and bone morphogenic protein 2 (BMP2) signaling pathways were 
involved in mediating the process. Additionally, primary cardiomyocyte cultures were used to 
explore mechanisms of toxicity at the cellular level. Viability, contractility, and reactive oxygen 
species (ROS) generation were evaluated in primary cardiomyocytes isolated from hearts of 
embryos exposed to PFOA in ovo or were exposed in vitro. Primary cardiomyocytes isolated 
from embryos exposed to PFOA in ovo functioned similarly to hearts of exposed hatchling 
chickens. Primary cardiomyocytes exposed in vitro responded differently, suggesting that the 
cardiotoxicity is likely from interference of PFOA in an early stage of heart development rather 
than from overt cytotoxicity to cardiomyocytes. In conclusion, this dissertation work indicates 
that PFOA induces morphological and functional alterations in hearts of chicken embryos and 
hatchling chickens, that mechanisms of the cardiotoxicity may involve PPARα and BMP2 
signaling pathways, and that PFOA is likely interfering in an early stage of heart development.  
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CHAPTER 1 INTRODUCTION 
 
1.1 Basic information on PFOA 
Perfluorooctanoic acid (PFOA) is a fluorinated chemical that belongs to the 
perfluoroalkyl acid (PFAAs) family of compounds. Chemically, PFOA is composed of an eight-
carbon atom chain, with one carbonyl group attached to one end and fluorine connected to all the 
carbons (Table 1.1). The carbon-fluorine bond is among one of the strongest chemical bonds, 
making PFOA highly stable, both in the environment and biota. PFOA, along with other 
perfluorinated compounds such as the fluorotelomers, was used as to make water and oil 
repellent coatings for textiles such as fabrics and leather (Fiedlera et al. 2010). The current major 
use of PFOA is as a synthesis aid in the production of fluoropolymers, such as 
polytetrafluoroethylene (PTFE), polyvinylidene fluoride, and fluoroelastomers. The 
fluoropolymers are then used in myriad industrial and consumer products such as automobiles, 
computers, non-stick cookware, and many others.  
 
1.2 Rationale of investigating the toxicity of PFOA 
 The plastics industry began using PFOA in early 1950s (Emmett et al. 2006); since then, 
its use has expanded and it has been released into the environment through legal discharge 
permits, accidentally through spills, and as a breakdown product of other fluorinated compounds 
(Zhu and Lin. 2008; Frömel and Knepper. 2010). Due to its high stability in environmental
media and biota, it is ubiquitously detectable around the world. Because of its extreme stability 
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Table 1.1 Chemical structure of PFOA and related perfluorinated compounds.  
 
Chemical name Structure 
Perfluorooctanoic acid (PFOA) 
 
Perfluorooctanesulfonic acid (PFOS) 
 
Perfluorohexanoic acid (PFHxA) 
 
Perfluoroheptanoic acid (PFHpA) 
 
Perfluorononanoic acid (PFNA) 
 
8:2 fluorotelomer alcohol (8:2 FTOH) 
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 and resistance to metabolic, photochemical, and microbial breakdown, it was previously 
considered nearly toxicologically inert; however, being chemically inert does not mean that it is 
unable to interfere with biological systems. Increasing concerns about its negative effects on 
human, wildlife, and ecosystem health arose between the 1980s and 1990s, and eventually lead 
to a stewardship program between the United States Environmental Protection Agency (USEPA) 
and eight major US manufacturers of PFOA to eliminate PFOA and related compounds from 
emissions and products by 2015 (USEPA 2013). As monitored by the Centers for Disease 
Control and Prevention (CDC), concentrations of PFOA in the serum of the general human 
population are decreasing. In samples collected between 2006 and 2007, the median 
concentration in the general human population was 4.3 ng/ml (CDC 2011); in samples collected 
between 2009 and 2010, the median concentration was 3.2 ng/ml (CDC 2013). However, 
exposure to PFOA likely will continue for a considerable amount of time as the half-life of 
PFOA in humans is up to several years. PFOA also is a breakdown product of certain fluorinated 
telomer alcohols and other precursor compounds of fluorinated polymers (Wang et al. 2005) and 
will likely continue to contaminate the environment. Additionally, the stewardship program to 
eliminate PFOA from emissions and products is limited to the US; production could still occur in 
other countries. As a result, it is necessary to investigate potential toxicities of PFOA, which will 
provide data to regulatory agencies for establishing safe exposure standards and/or minimizing 
the risk to exposed populations.  
 
1.3 Levels of PFOA exposure in humans 
PFOA exposure to the general human population, as previously mentioned, is at a 
relatively low level. Current data from the CDC indicates that the median serum concentration of 
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PFOA in the general human population was 3.2 ng/ml in samples collected between 2009 and 
2010 (CDC 2013). The full exposure pathway in the general human population has not been fully 
characterized. However, contaminated drinking water in areas surrounding fluorochemical plants 
and occupational exposures lead to much higher exposure levels in certain populations relative to 
the general human population. In an area of West Virginia contaminated with PFOA by a 
manufacturing plant, epidemiological studies of the exposed populations reported a median 
PFOA serum concentration of 26.6 ng/ml, with a high value of 17,556.6 ng/ml (Steenland et al. 
2009). Another study reported a median serum value of 75.7 ng/ml in residents of communities 
surrounding a fluoropolymer production facility (Hoffman et al. 2011). Serum concentrations as 
high as 5100 ng/ml have been reported in occupationally-exposed humans (Olsen et al. 2007). 
PFOA exposure potentially poses a much higher health risk to these populations and additional 
data on the toxicity of PFOA will help to protect these susceptible populations.   
 
1.4 Adverse health effects associated with PFOA exposure 
Epidemiological studies of the effects of PFOA on human development have been carried 
out in areas of known high exposures such as West Virginia-Ohio (US) and the Faroe Islands 
(Denmark). Fluorochemical plants contaminated the drinking water in the West Virginia-Ohio 
area. The Faroe Islands population was exposed to PFOA due to their frequent consumption of 
marine mammals (Weihe et al. 2008). In the West Virginia-Ohio population, modest associations 
of PFOA serum concentrations with preeclampsia and birth defects were found (Stein et al. 
2009). PFOA exposure was associated with elevated serum cholesterol and uric acid levels in 
children and adolescents from this population as well (Frisbee et al. 2010). Additionally, 
decreased serum triiodothyronine levels and elevated thyroxine levels (Knox et al. 2011) and 
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elevated alanine aminotransferase levels following PFOA exposure were detected in human 
samples (Gallo et al. 2012). Associations between PFOA exposure and testicular, kidney, 
prostate, and ovarian cancers and non-Hodgkin lymphoma were also reported (Vieira et al. 
2013). Conversely, Nolan et al. (2009; 2010) reported that elevated PFOA exposure in this 
population was not associated with lowered birth weight or gestational age, labor or delivery 
complications, or maternal risk factors such as eclampsia or diabetes. However, lack of umbilical 
cord serum PFOA concentrations made it difficult to assess actual fetal exposures and more work 
is needed before conclusions can be made regarding the potential negative health effects of 
PFOA in this human population. In a recent study of the Faroe Islands population, developmental 
exposure to a mixture of perfluorinated compounds (PFCs) was associated with decreased 
humoral immune responses to vaccinations in children between five and seven years old.  
(Grandjean et al. 2012).  
In laboratory animal models, PFOA is known to activate PPARα to induce hepatic, 
pancreatic, and testicular cell cancers (Biegel et al. 2001), endocrine disruption (Olsen et al. 
1998), and immunotoxicity (DeWitt et al. 2008). In addition, PFOA has been reported to induce 
developmental effects, including retarded development and decreased fetal survival (Wolf et al. 
2007). An important reason for this study is that the precise mechanisms of developmental 
toxicity for PFOA have not yet been fully elucidated.  
 
1.5 Heart development 
The heart is one of the earliest organs to develop and become functional during the 
embryonic stage; proper circulation is a prerequisite for many other organs to properly develop 
(Farrell and Kirby 2001). The heart is composed of cells derived from several different origins, 
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and yet these cells form a morphologically and functionally refined organ in a relatively short 
time (Farrell and Kirby 2001; Kirby 2002). In chickens, the primary heart tube starts to develop 
within hours of incubation, twists into the beginnings of four chambers by day four and is fully 
four chambered by day seven  (Farrell and Kirby 2001; Kirby 2002). In a very short time 
window, many signals regulate heart development, which makes it vulnerable to exogenous 
disruptions that may induce abnormalities of form or function. Because heart development 
happens in such a short time, the window during which exposure to an exogenous disruption 
occurs is a crucial factor in developmental cardiotoxicity. Signaling pathways important in 
regulating heart development and that may be impacted by developmental PFOA exposure 
include TGF-β superfamilies, transcription factor nkx2.5 and GATA4 (Farrell and Kirby 2001; 
Kirby 2002). 
1.5.1 TGF-β superfamilies in heart development 
Certain members of the TGF-β superfamilies, including BMP2, BMP4, TGF-β, and activin play 
important roles in early heart development, especially in heart field mesoderm induction (Kirby 
2002). BMP2 is expressed in the anterior lateral endoderm, which is the crucial induction center 
for heart field formation (Ladd et al. 1998). In the precardiac mesoderm, application of BMP2 in 
vivo induces the expression of cardiac specific transcription factors Nkx 2.5 and GATA4, 
whereas application of the BMP2 antagonist noggin blocks cardiac induction (Schultheiss et al. 
1997; Schneider et al. 2001). Upon binding to BMP2, BMP2 receptors undergo 
autophosphorylation, and then phosphorylate the second messenger SMAD1/5/8, which then 
forms a heteromeric complex with SMAD4 and transfers to the nucleus to regulate gene 
expression (Chen et al. 2004). Figure 1.1 contains a schematic of the BMP2 signaling pathway.  
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1.5.2 Nkx2.5 and GATA4 in heart development 
Nkx2.5 is a homeodomain protein that acts as a transcription factor and regulates many 
downstream genes of cardiac development, including Lrrn1, Elovl2, Safb, Slc39a6, Khdrbs1, 
Hoxb4, Fez1, Ccdc117, Jarid2, Nrcam, and Enpp3 (Barth et al. 2010). Thus Nkx2.5 regulates 
many aspects of cardiac development. In the early stage of heart development, Nkx2.5 plays an 
important role in cardiac precursor differentiation and proliferation (Harvey et al. 2002; Kirby 
2002). Later developmental events such as outflow tract formation also require Nkx2.5 (Harvey 
et al. 2002). Loss of Nkx2.5 leads to failed cardiac looping and deficient myocardial 
differentiation, which then leads to lethality in mouse embryos (Tanaka et al. 1999). GATA4 is a 
zinc finger transcription factor that also plays a crucial role in cardiac development (Peterkin et 
al. 2005).  Examples of the target genes of GATA4 include LHX9, BCL2 and N-cadherin 
(Smagulova et al. 2008; Kobayashi et al. 2006; Zhang et al. 2003). Lack of GATA4 expression 
leads to abnormal folding, failure of heart primordial fusion, and dendoderm defects, which also 
lead to lethality in mouse embryos (Kuo et al. 1997; Molkentin et al. 1997). Nkx 2.5 and GATA4 
could regulate each other’s expression (Sepulveda et al. 2002). Additionally, Nkx2.5 is regulated 
by the BMP2 pathway (Prall et al. 2007), thus BMP2, Nkx2.5, and GATA4 are closely 
connected in their regulation of heart development. 
 
1.6 Heart development and environmental contaminants 
Heart development is a complex process involving many signaling pathways that regulate 
development in a very short time. This makes heart development especially sensitive to 
exogenous disruptions. When environmental contaminants mimic or block endogenous signals  
and/or ligands, or indirectly alter signaling pathways, for example, by changing phosphorylation 
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Figure 1.1 BMP2 signaling pathway. When BMP2 ligands bind to the receptor, BMP receptor 
type II phosphorylates BMP receptor type I, which then phosphorylates the second messenger 
SMAD1/5/8, and forms the heteromeric SMAD complex with SMAD4. The complex 
translocates to the nucleus and acts as a transcription factor, regulating the expression of 
important heart development-related genes, such as Nkx2.5 and GATA4.  
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states when the heart is developing, the risk of malformations increases. Major malformations 
will lead to congenital heart diseases (CHD). CHD is defined as defects present in the structure 
of the heart and/or great vessels at birth (Go et al. 2013), and is the leading cause of infant death, 
accounting for 29% of total infant mortality in the U.S. (Go et al. 2013). 36,000 infants are born 
in the U.S. with congenital heart disease every year (Go et al. 2013). Major types of congenital 
heart disease include visceroatrial heterotaxia or right–left axis defects, alignment defects such as 
dextroposed aorta and tricuspid atresia; septation defects such as atrioventricular canal, 
ventricular septal defects, persistent truncus arteriosus, aortic stenosis and interrupted aortic arch 
(Kirby 2002). 
Examples of agents that induce developmental cardiotoxicity include: 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), which inhibits epicardium and proepicardium development 
in zebra fish (Plavicki et al. 2012); trichloroethylene alters shear stress gene expression and 
function in developing chicken hearts (Makwana et al. 2010); and finally, PFOS, a PFC that 
shares some properties with PFOA, can impair the cardiac development of marine medaka 
(Huang et al. 2011). Aside from agents that can induce specific types of developmental 
cardiotoxicity, environmental toxicants also may induce developmental cardiotoxicity via 
indirect mechanisms, such as interference with energy metabolism (Hantson et al. 2012). More 
attention should be paid to the potential risks that environmental contaminants pose on 
developing organs, including the heart, because of the wide range of environmental contaminants 
and the high human health risk associated with disrupted organ development, including heart 
development. 
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1.7 PFOA and heart development 
 Presently, no association has been reported between developmental exposure to PFOA 
and an increased incidence of CHD in human populations. However, it is never easy to establish 
associations between exposure to a single chemical and the etiology of a specific disease. 
Associations, if present, between PFOA and CHD will likely be confounded by other risk 
factors, including exposure to multiple chemicals. Because PFOA does induce a wide range of 
toxicities, including immunotoxicity, developmental toxicity, and disturbances to energy 
metabolism, it may induce CHD through multi-system toxicity. However, additional 
investigations are still necessary to determine whether exposure to PFOA (and other PFCs) 
contributes to the etiology of CHD.   
 
1.8 Heart development and cardiovascular diseases 
The etiology of cardiovascular disease is complex. During 2009, over 2150 Americans 
died of cardiovascular disease every day and every one in six deaths in the US in 2009 was due 
to cardiovascular diseases (Go et al. 2013). Given that cardiovascular disease is the leading cause 
of morbidity and mortality in the US, identification of potential risk factors can help to reduce 
the disease burden on society. Many risk factors such as smoking and diet have been identified, 
but many more remain unknown. Disruption of heart development during the embryonic stage by 
exogenous agents could be a risk factor. While profound disruption of heart development likely 
will cause congenital heart disease, minor disturbances that have no detectable effects early in 
life could lead to a higher heart disease incidence later in life (Langley-Evans et al. 2006; 
Eriksson et al. 2006). If we can identify these disturbances, such as exposure to environmental 
contaminants, it is possible to take measures to decrease the incidence of cardiovascular disease.  
 11 
 
1.9 Chicken embryo models in developmental toxicity studies 
The history of using chicken embryos as a model in developmental toxicology is very 
long. In the early nineteenth century, Etienne Geoffroy Saint-Hilaire had already started using 
chicken embryos to study the effects of various environmental conditions on development 
(Charon. 2004). There are several advantages to using chicken embryos in developmental 
toxicological studies. Eggs are laid before major development begins, so in ovo development is 
relatively free of maternal influences. Because of the long history of using chicken embryos, the 
embryonic development of chickens has been very intensely studied and well defined, making it 
very easy to identify abnormalities associated with exposure to toxicants. It is also possible to 
isolate embryonic tissues at specific ages relatively easily (Henshel et al. 2003). In the current 
study, hearts from embryonic day 19 (ED19) chickens were used for histology as they are the 
size of hatchling chickens but have not yet undergone the highly energetic process of hatching 
and thus are slightly less variable. ED4 embryos were easily collected from eggs and were ideal 
tissues for PCR and western blot. Under a dissection microscope, hearts of ED6 embryos were 
dissected so that expression of heart-specific genes and protein levels could be measured 
expressly in hearts. The chicken embryo model facilitated this dissertation work and has proved 
to be especially useful in developmental studies.  
 
1.10 Rationale of investigating developmental cardiotoxicity induced by PFOA 
Although much work has been done regarding developmental toxicity induced by PFOA, 
the mechanisms of retarded development and decreased fetal survival have not yet been 
elucidated. I hypothesize that as the cardiovascular system is one of the earliest organ systems to 
develop, cardiotoxicity induced by developmental PFOA exposure may contribute to decreased 
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fetal survival. Moreover, published data suggest that PFOA has the potential to interfere with 
heart development. Possible molecular targets of PFOA that could induce developmental 
cardiotoxicity are: PPARα, inflammatory cytokines, and the BMP2 signaling pathway.  
1.10.1 PPARα 
Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that are 
capable of producing hepatic peroxisome proliferation on activation (Dreyer et al. 1992). Upon 
activation, PPARs heterodimerize with the retinoid X receptor and bind to the promoter region of 
target genes controlling fatty acid uptake, utilization, oxidation, and storage pathways (Feige et 
al. 2006). The PPAR family includes PPARα, PPARβ/δ and PPARγ (Dreyer et al. 1992). Since 
PFOA is known to activate PPARα (Rosen et al. 2008) and PPARα is expressed in relatively 
abundant levels in the heart (Lee et al. 2013), PPARα is one of the most probable targets of 
PFOA in developmental cardiotoxicity. To date, no published data indicate that PPARα is 
directly involved in heart development. However, PPARα is known to regulate energy 
metabolism (Nicholls et al. 2012). PPARα overexpression could lead to a cardiac phenotype 
similar to that observed in hearts of diabetics (Finck et al. 2002). Considering the critical role of 
PPARα in modulating fatty acid β-oxidation, the major energy resource of the heart, it is possible 
that PPARα is involved in developmental cardiotoxicity via energy metabolism modulation. 
Additionally, PPARα activation is associated with anti-inflammatory and anti-oxidant effects 
(Chen et al. 2007); PPARα could affect heart development via altered ROS generation as well.  
ROS generation is one of the major factors that mediate cardiotoxicity (Berthiaume and Wallace 
2007). While PPARα activation has been reported as a protective factor against ROS in 
myocardiac diseases (Ibarra-Lara et al. 2013), Sambandam et al. (2005) reported that chronic 
activation of PPARα is detrimental to ischemic hearts. In an early clinical trial, increased overall 
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mortality was observed in subjects who took the PPARα agonist clofibrate and who also had a 
history of myocardial diseases (Backes et al. 2007). These reports demonstrate the potential of 
PPARα activation to induce detrimental effects in the heart, possibly via excessive fatty acid β-
oxidation followed by ROS generation. In a developing chicken embryo, β-oxidation of fatty 
acids derived from yolk lipids is the major energy resource (Stock and Metcalfe 1987). These 
higher basal levels of β-oxidation of fatty acids and relatively high vulnerability of the 
developing embryo to ROS generation (Surai 1999) suggest that PPARα may partially mediate 
developmental cardiotoxicity induced by PFOA exposure. In summary, interference of PPARα 
signaling by PFOA could potentially affect heart development via mechanisms such as alteration 
of energy metabolism and excessive ROS generation.  
1.10.2 Inflammatory cytokines 
Inflammatory cytokines play an important role in cardiotoxicity (Torre-Amione 2005). 
The induction/suppression of inflammatory cytokine production could potentially contribute to 
the developmental cardiotoxicity that we observed with PFOA exposure, as cytokines could 
interfere with signaling pathways that are important to heart development. For example, the 
TGF-β superfamily is vulnerable to interference by inflammatory cytokines. IL-1β can modulate 
TGF-β signaling via IL-6 activation (Luo et al. 2009) and increased TNF-α can suppress the 
TGF-β receptor population (Yamane et al. 2003). The effects of PFOA exposure on 
inflammatory cytokines suggest both pro- and anti-inflammatory effects. While Taylor et al. 
(2005) reported that PFOA has potency similar to dexamethasone, a known anti-inflammatory 
agent, against carageenan-induced edema and thermal hypersensitivity, Yang (2010) reported 
that PFOA exposure increased expression of various inflammatory cytokines in Oryzias latipes. 
In this dissertation, the impact of PFOA on inflammatory cytokines in chicken embryos was 
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assessed to elucidate the role of inflammatory cytokines in PFOA-induced developmental 
cardiotoxicity.  
1.10.3 BMP2 signaling pathway 
The BMP2 signaling pathway belongs to the TGF-β superfamily. As detailed in 1.5.1, the 
BMP2 signaling pathway plays important roles in heart development. Not only is BMP2 itself 
crucial for heart field induction, but the downstream genes regulated by BMP2 also include the 
heart-development-important transcription factors Nkx2.5 and GATA4 (Kirby 2002). 
Furthermore, as mentioned in 1.10.2, there is evidence that PFOA could indirectly affect the 
BMP2 signaling pathway by interfering with inflammatory cytokines. The ability of PFOA to 
interfere with the BMP2 ligand, receptor, and second messengers was assessed as a potential 
mechanism of toxicity for PFOA induced developmental cardiotoxicity.   
 
1.11 Aims of the study 
The aim of this study was to assess the developmental cardiotoxicity induced by PFOA 
exposure in chicken embryos and hatchling chickens and to explore the underlying mechanisms. 
Specifically, there were three aims of the study: 
Specific aim 1: To assess the morphological and functional alterations in hearts from late 
stage chicken embryos and hatchling chickens following developmental exposure to PFOA.  
Rationale for specific aim 1: It is most important to first confirm that PFOA does induce 
developmental cardiotoxicity. This was the basis for all of the subsequent studies. To evaluate 
cardiotoxicity, morphological and functional parameters were endpoints most relevant to human 
health. These results not only indicated cardiotoxicity, but also provided hints of the potential 
mechanisms.  
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Specific aim 2: To assess the molecular mechanism of PFOA-induced developmental 
cardiotoxicity, including PPARα, the BMP2 pathway, Nkx2.5/GATA4, and inflammatory 
cytokines.  
Rationale for specific aim 2: Determining the molecular mechanism of toxicity is 
necessary to fully understand how PFOA disrupts cardiac development. As PFOA is known to 
activate PPARα, signals associated with the PPARα pathway were assessed as the most plausible 
mechanism. PFOA also is known to interfere with inflammatory cytokines; the latter potentially 
can interfere with the BMP2 signaling pathway, so both inflammatory cytokines and targets 
within the BMP2 signaling pathway were assessed as well. Moreover, as the BMP2 signaling 
pathway is known to induce Nkx2.5 and GATA4 expression, both of which are important 
transcription factors in heart development, they also were assessed.   
Specific aim 3: To assess PFOA-induced developmental cardiotoxicity at the cellular 
level, including viability, contractility, and ROS generation.  
Rationale for specific aim 3: While a mechanism of PFOA-induced developmental 
cardiotoxicity was suggested by data generated in specific aim 2, others may exist and still 
remain unknown. This aim was designed to discover additional information regarding the 
mechanism of cardiotoxicity, mainly at the cellular level. This aim asked whether PFOA induced 
developmental cardiotoxicity via overt cytotoxicity of PFOA to cardiomyocytes or via an earlier, 
upstream signaling pathway. To answer this, primary cardiomyocyte cultures isolated from 
hearts of chicken embryos pre-exposed to PFOA (exposed to PFOA in ovo) or exposed to PFOA 
in vitro (directly exposed to PFOA in medium) were assessed and the responses were compared 
to distinguish whether PFOA impacted cells directly or by disturbing a process during 
development.    
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CHAPTER 2 PERFLUROOCTANOIC ACID INDUCES DEVELOPMENTAL 
CARDIOTOXICITY IN CHICKEN EMBRYOS AND HATCHLINGS  
 
Abstract 
Perfluorooctanoic acid (PFOA) is a widespread environmental contaminant that is 
detectable in serum of the general U.S. population. PFOA is a known developmental toxicant 
that induces mortality in mammalian embryos and is thought to induce toxicity via interaction 
with the peroxisome proliferator activated receptor α (PPARα). As the cardiovascular system is 
crucial for embryonic survival, PFOA-induced effects on the heart may partially explain 
embryonic mortality. To assess impacts of PFOA exposure on the developing heart in an avian 
model, we used histopathology and immunohistochemical staining for myosin to assess 
morphological alterations in 19-day-old chicken embryo hearts after PFOA exposure. 
Additionally, echocardiography and cardiac myofibril ATPase activity assays were used to 
assess functional alterations in one-day-old hatchling chickens following developmental PFOA 
exposure. Overall thinning and thinning of a dense layer of myosin in the right ventricular wall 
were observed in PFOA-exposed chicken embryo hearts. Alteration of multiple cardiac structural 
and functional parameters, including left ventricular wall thickness, left ventricular volume, heart 
rate, stroke volume, and ejection fraction were detected with echocardiography in the exposed 
hatchling chickens. Assessment of ATPase activity indicated that cardiac myofibril calcium 
independent ATPase activity also was elevated by developmental PFOA exposure. In summary, 
the heart appears to be a developmental target of PFOA. Additional studies will investigate 
mechanisms of PFOA-induced developmental cardiotoxicity. 
Published on Toxicology. 293, 97–106. Jiang, Q., Lust, R.M., Strynar, M.J., Dagnino, S. and DeWitt, J.C. Reuse in 
dissertation permitted by Elsevier (http://www.elsevier.com). 
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2.1 Introduction 
Perfluoroalkyl acids (PFAAs) are fluorinated compounds used to manufacture materials 
for myriad consumer and industrial products, including nonstick, stain-repellant, water repellant, 
and fire-retardant coatings. Perfluorooctanoic acid (PFOA) is a PFAA that is a polymerization 
aid used to manufacture fluorinated polymers and elastomers, the most well known being 
polytetrafluoroethylene (PFTE). According to the current major manufacturer of PFOA, a 
minimal amount of PFOA is still present in end-products (DuPont 2011), which can leach out 
and may contribute to exposures. PFOA also is a breakdown product of certain fluorinated 
telomer alcohols and other precursor compounds of fluorinated polymers (Wang et al. 2005). 
PFOA has become a public health concern because it is present in environmental media and 
biota. 
Increasing reports of PFOA-induced toxicity led to a stewardship program between major 
flourochemical manufacturers and the U.S. Environmental Protection Agency (USEPA). The 
goal of the stewardship program is to eliminate PFOA and precursor products that can break 
down to PFOA by 2015 (USEPA 2011). However, as PFOA does not bio-degrade, it persists in 
the environment; it is ubiquitously found in environmental samples and in serum of the world 
population. The median serum concentration in the U.S. population reported in 2007-2008 was 
4.3 ng/mL (CDC 2011). In an area of the Mid-Ohio Valley contaminated with PFOA by a 
manufacturing plant, epidemiological studies of exposed populations reported a median PFOA 
serum concentration of 26.6 ng/mL, with a high value of 17,556.6 ng/mL (Steenland et al. 2009). 
Epidemiological studies of the effects of PFOA on human embryonic and fetal development of 
residents living in the Mid-Ohio Valley have not produced clear associations with birth 
outcomes. Stein et al. (2009) reported modest association of PFOA serum concentrations with 
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preeclampsia and birth defects in the Mid-Ohio Valley population. Additional studies reported 
that elevated PFOA exposure in this population was not associated with increased risk of 
lowered birth rate or gestational age (Nolan et al. 2009) or with congenital anomalies, labor or 
delivery complications, or maternal risk factors such as eclampsia or diabetes (Nolan et al. 
2010). Although Apelberg et al. (2007) reported PFOA concentrations in umbilical cord serum 
for the general U.S. population (0.3-7.1 ng/mL), Nolan et al. (2009, 2010) did not measure 
PFOA concentrations in umbilical cord serum, so no corresponding cord serum levels are 
available for the highly exposed Mid-Ohio Valley U.S. population. Regardless, given the PFOA 
serum concentrations reported for this population and the potential for PFOA to affect 
development, additional studies of more subtle developmental effects are necessary. 
In laboratory models, PFOA induces multisystem and data from studies of such models suggest 
that it is an agonist of the peroxisome proliferator activated receptor α (PPARa). Effects in 
laboratory models include hepatic, pancreatic and testicular cancer (Biegel et al. 2001), 
endocrine disruption (Olsen et al. 1998), and immunotoxicity (DeWitt et al. 2008). In addition, 
PFOA has been reported to induce developmental effects, including retarded development, 
decreased fetal survival and increased deformities in animal models (Wolf et al. 2007). In 
humans, epidemiology studies indicate that PFOA exposure is associated with elevated serum 
cholesterol and uric acid levels (Steenland et al. 2010). 
Measurable serum concentrations and accompanying changes in cholesterol levels in 
exposed human populations warrant investigation of additional health effects of PFOA, 
especially effects related to the cardiovascular system. In addition, reasons for increases in fetal 
mortality associated with developmental PFOA exposure (Wolf et al. 2007; Lau et al. 2004, and 
DeWitt et al. 2009) are unknown. As cardiovascular development is a complex and delicate 
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process, with numerous signaling activities vulnerable to exogenous disruptions from exposure 
to pathogens, drugs and environmental pollutants, altered cardiovascular development may affect 
embryo survival. Several agents have been reported to alter cardiovascular development. 
Lipopolysaccharide exposure induces cellular hypertrophy in H9c2 myocardiac cells and alters 
the calcineurin/NFAT-3 signaling pathway (Liu et al. 2008). Adriamycin (doxorubicin), an 
antitumor drug used to treat leukemias, lymphomas and neoplasms, induces ventricular septal 
defects, dextroposition of the aorta, and aortic arch anomalies in a dose-related manner when 
topically administered to five-day-old chicken embryos (Takaqi et al. 1989). Adriamycin likely 
decreased embryonic cardiac blood flow and inhibited rapidly exchangeable calcium within 
cardiac cells (Takaqi et al. 1989). In addition, adriamycin induces dose-dependent 
cardiomyopathy, likely via iron oxidation and oxygen free radical formation, which limits its 
therapeutic applications (Shi et al. 2011). Environmental contaminants also have been reported to 
induce cardiotoxicity. 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD) application enlarged left and 
right ventricles, thickened ventricular septa and thinned left ventricle walls in chicken embryos 
(Walker et al. 1997) and 3,3’,4,4’,5-pentachlorobiphenyl (PCB-126) exposure decreased 
myocyte proliferation in zebra fish, possibly by affecting hemodynamics (Grimes et al. 2008). 
Taken together, these studies indicate that the developing heart is sensitive to exogenous 
perturbations. Given PFOA’s developmental toxicity in laboratory models, presence in humans 
and wildlife, and possible effects on endogenous compounds associated with heart disease, we 
investigated PFOA’s effects on developing hearts. As avian and mammalian cardiovascular 
development is similar and avians lack a direct maternal influence, avian embryos are ideal 
models for developmental toxicity studies. This is the first study to assess both morphological 
and functional changes in avian hearts developmentally exposed to PFOA.  
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2.2 Materials and methods 
2.2.1 Animals 
Fertile chicken (Gallus gallus) eggs were purchased from North Carolina State 
University Poultry Research Center (Raleigh, NC). Eggs were cleaned with 20% povidone 
iodine, candled to outline air cells in pencil on shells, weighed, given ID numbers, and evenly 
distributed by weight among doses. Due to incubator space limitations, eggs were incubated in 
eight batches of 40-58. Uninjected eggs were included in each batch as environmental controls. 
2.2.2 Chemicals 
 Sunflower oil was purchased from Spectrum Organic Products, LLC (Boulder, CO). 
PFOA and other chemicals (if not otherwise mentioned) were purchased from Sigma-Aldrich 
(St. Louis, MO). 
2.2.3 Egg injection and incubation 
 Injection procedures were as described in Henshel et al. (2003). Briefly, PFOA was 
suspended in sunflower oil and vortexed before injection into each egg. An awl was used to drill 
a 1 millimeter (mm) hole into the middle of air cells and PFOA doses of 0, 0.5, 1 and 2 
milligram per kilogram (mg/kg) of egg weight were injected with a gel-loading pipette tip. Stock 
solutions were prepared so that 0.1 microliter (µl) of solution per gram of egg weight resulted in 
the appropriate mg/kg concentration. Doses were chosen based on published reports of PFAAs 
injected into chicken eggs and were not expected to induce dose-related mortality. After 
injection, a drop of melted paraffin sealed injection holes. Eggs were incubated in a Lyon Roll-X 
incubator (Chula Vista, CA) set at 99.5-100ºF dry bulb and  87-88ºF wet bulb. Eggs were 
candled every 2-3 days; infertile/undeveloped/dead eggs were removed. After external pipping 
eggs were placed individually into containers large enough for the hatched chickens and 
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transferred to a larger incubator (G.Q.F. Manufacturing Co., Savannah, GA). Hatchling chickens 
were kept in a warmed brood box until euthanasia. All procedures were approved by the East 
Carolina University Institutional Animal Care and Use Committee. 
2.2.4 Histology 
At embryonic day 19 (D19; two days prior to hatch), embryos were removed from eggs 
and quickly decapitated. Whole embryo, yolk, heart, and liver weights were recorded. Hearts 
were excised, rinsed in ice cold saline to fully dilate ventricles, fixed in 10% phosphate buffered 
formalin for 24h, and cut transversely. Cuts were made approximately 60% of the length of the 
heart from the ventricular apex (Figure 2.1A). Ventricular tissues were processed routinely 
(Thermo Scientific Shandon Citadel 1000, Waltham, MA), embedded in paraffin, and sliced at 
six micrometer (µm) per section on a rotary microtome (Thermo Scientific, HM 315 Waltham, 
MA). The septomarginal trabecula was used to maintain a relatively constant position to ensure 
that ventricular wall measurements were made at the same location within each heart (Figure 
2.1D-F). For routine histology, hearts were stained with Harris modified hematoxylin (Fisher 
Scientific, Fair Lawn, NJ) and Eosin Y solution (Harleco, Gibbstown, NJ) (H&E). Adobe 
Photoshop (San Jose, CA) and SPOT advance (SPOT imaging, Sterling Heights, MI) with rulers 
(made in Berkeley Logo, Berkeley, CA) was used to measure the thickness of the right 
ventricular wall (Figure 2.1B). Average right ventricular wall thickness was normalized to whole 
heart weight to minimize potential PFOA-induced effects on body weight or developmental 
stage. 
2.2.5 Immunohistochemistry 
 Immunohistochemistry was used to selectively stain sarcomere myosin. Antigen Unmask 
Solution, Vectastain ABC Kit (Mouse IgG), and peroxidase substrate Kit were purchased from 
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Vector Labs (Burlingame, CA); MF-20 antibody against myosin was purchased from the 
Developmental Studies Hybridoma Bank (University of Iowa, Iowa city, IA). Sections were 
deparaffinized, blocked in serum albumin for one hour, and incubated with 1:50-1:100 MF-20 in 
phosphate buffered saline with 0.5% tween-20 for 30 minutes at room temperature. Secondary 
antibody was applied at 1:75 and 3,3'-Diaminobenzidine (DAB) with nickel solution was added 
for color development. Sections were counter-stained with hematoxylin for 20 seconds and cover 
slipped. Although myosin is present in all myocytes, a dense layer of myosin selectively stained 
in the right ventricular wall was used as the measurement target (Figure 2.1C). Measurements 
similar to those on H&E stained sections were collected, with an additional measure to evaluate 
the myosin dense layer, which also was normalized to whole heart weight. 
2.2.6 Cardiac ultrasound on hatchling chickens 
Within 24 hours post-hatch, hatchlings from all dose groups (including the vehicle 
control group) were evaluated with an ultrasound instrument (Visualsonics Vevo 2100, Toronto, 
Ontario, Canada) for direct cardiac function measurement. Ultrasound measurements were 
collected from hatchlings in random order to spread time and handling-related differences across 
dose groups. Hatchlings were enclosed in a stockinette (stretchable, breathable gauze) so that 
they could be restrained for echocardiography without damaging their feathers. A hole was cut in 
the torso of the stockinette and ultrasound gel was applied directly to the torso of each hatchling. 
Heart rate, stroke volume, ejection fraction (fraction of blood pumped out of the right and left 
ventricles with each heart beat), fraction shortening (the fraction of any diastolic dimension that 
is lost in systole), left ventricular posterior wall dimension, left ventricular volume and mass 
were measured and analyzed; the person performing the analysis was blind to the dose group 
assignments. Although histology was evaluated on the right ventricular wall, the left ventricle is 
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a more accessible target for echocardiography. While we are aware of the potential limitation of 
taking histological and functional measurements on different ventricles, the closely related 
functions of the ventricles enable us to evaluate the effects of PFOA exposure on overall heart 
development. 
2.2.7 Cardiac myofibril ATPase assay 
To supplement the ultrasound data and provide an additional functional measure, animals 
were euthanized shortly after ultrasound measurements and a cardiac myofibril ATPase assay 
was used to determine if calcium–activated, magnesium-dependent ATPase activity was altered. 
The method used was adapted from Candau et al. (2003) with modifications. Hearts were 
removed as described for the morphology study and stored at -80ºC. Thawed ventricular tissue 
(200 milligram (mg) per animal) was homogenized in 1 milliliter (mL) homogenization buffer, 
which consisted of tris (hydroxymethyl) aminomethane (Tris) 50 millimolar (mM), 
ethylenediaminetetraacetic acid (EDTA) 5mM, sodium chloride (NaCl) 100mM, potassium 
chloride (KCl) 2mM, 1:100 protease inhibitor (Thermal Scientific, Rockford, IL), 0.5% Triton, 
pH 7.2-7.4 and then centrifuged at 2000 relative centrifugal force (RCF, g) (4ºC, 15 minutes). 
Pellets were resuspended in 1 mL wash buffer (KCl 100mM and 1:100 protease inhibitor) and 
centrifuged at 2000g (4ºC, 15 minutes). Washes were repeated four times. Prior to the last 
centrifugation, suspensions were filtered through 70 µm nylon cell strainers (BD Falcon, 
Bedford, MA) to exclude tissue debris. Final pellets were resuspended in storage buffer (Tris 
50mM, potassium acetate (K-acetate) 100mM, KCl 5mM and 1:100 protease inhibitor, pH 7.2-
7.4) and protein concentration was determined (Thermo Scientific, Rockford, IL). 
Protein concentration was adjusted to 50 microgram per milliliter (ug/mL), and samples 
were divided into calcium-dependent ATPase groups (storage buffer plus 3mM magnesium 
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chloride and 0.1mM calcium chloride) and calcium-independent ATPase groups (storage buffer 
plus 3mM magnesium chloride and 10mM ethylene glycol tetraacetic acid (EGTA)). Samples 
were equilibrated at room temperature for 5 minutes and ATP (final concentration 0.5mM) was 
added to initiate reactions. After 30 minutes at room temperature, PiGoldLock (Innova 
Biosciences, Babraham, Cambridge, UK) with 1:100 accelerator was added to stop reactions and 
visualize free inorganic phosphate. Two minutes later, stabilizer (Innova Biosciences, Babraham, 
Cambridge, UK) was added to stop ATP hydrolysis. Samples were incubated at room 
temperature for 30 minutes to develop color completely and read at 630 nanometer (nm) (Biotek 
Synergy HT plate reader, Winooski, VT). 
2.2.8 Serum PFOA concentration 
Samples were prepared as described in Reiner et al. (2009). Briefly, thawed serum was 
vortexed for 30 seconds and 25 microliter (µl) aliquots were placed into 5 mL polypropylene 
tubes (BD Falcon, Franklin Lakes, NJ) and denatured with 100 µl of 0.1 molar (M) formic acid 
containing approximately 5 ng 
13
C2-PFOA. Samples were vortexed for 1 minute (min), received 
1.0 mL of cold acetonitrile to precipitate proteins, were vortexed for 1 min, and then centrifuged 
at 10,000 revolutions per minute (RPM) for 2 min to pelletize proteins. Aliquots of extracts (200 
ul) were combined with 200 µl of 2 mM ammonium acetate for liquid chromatography–mass 
spectrometry (LC/MS-MS) analysis. All unknowns, replicates, method and matrix blanks, and 
quality control (QA/QC) samples were prepared in this fashion. Standard curve preparation was 
matrix matched. Standards were prepared by adding 25 µl of control Pel-Freez CD1 mouse 
serum into a 5 mL tube and then spiking in a corresponding mass of PFOA in methanol (0.250 – 
1,250 ng) relating to 10 to 50,000 ng PFOA/mL of serum. This was covered by two standard 
curve ranges (10 – 500 ng/mL) and (500 – 50,000 ng/mL). Standards were likewise treated as all 
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other samples. Samples that did not fall in the lower standard curve range were re-run with a 
slightly modified method. The 25 µl serum sample was diluted with 2.0 mL of 0.1 M formic 
acid, 200 µl was sampled and was added to 2.0 mL of acetonitrile containing approximately 62.5 
ng of 
13
C2-PFOA. This acetonitrile extract was then used to prepare the samples further as 
described above. 
Samples were quantitated using a Waters Acquity UPLC coupled to a Quatro Premier XE 
tandem mass spectrometry (MS/MS) (Waters, Milford, MA). Samples were run in a batch to 
include double blanks (solvent blank), a method blank, matrix blank (blank serum), standards, 
QC samples, replicates, and unknowns in sequence. Standards were run at the beginning and end 
of analytical batches, and QC samples interspersed in analytical batches. Quality control samples 
consisted of pooled mouse serum spiked at six concentrations over the analytical range. Average 
accuracy of QC pools samples was 94.1% with a %RSD of less than 10% for all samples (n = 
18). PFOA was monitored via the transition 413-369 and 413-169 and for the 
13
C2-PFOA 415-
370. Samples were run using an isocratic (50:50) mobile phase consisting of 2 mM ammonium 
acetate aqueous solution with 5% methanol (solvent A) and 2 mM ammonium acetate in 
acetonitrile (solvent B). Samples were integrated using the equipment software and corrected if 
necessary by the operator. 
2.2.9 Statistical Analysis 
All data were analyzed by one way Analysis of variance (ANOVA) by dose. Statistical 
significance was determined when P < 0.05. When ANOVA revealed a statistically significant 
model, post-hoc t-tests were performed to determine statistical significance between dose groups. 
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2.3 Results 
2.3.1 General toxicity 
Mortality, hatchability, yolk-free body weight, and relative heart and liver weights for 
both D19 chicken embryos and hatchling chickens are reported in Table 2.1. In D19 embryos, 
mortality in the 2 mg/kg dose group was statistically increased by 75.7% relative to the vehicle 
control group. No other differences in general toxicity parameters were observed in D19 
embryos. In hatchling chickens, relative liver weight was statistically increased by 28.6% in the 
0.5 mg/kg and 1 mg/kg dose groups relative to the vehicle control group. No other differences in 
general toxicity parameters were observed in hatchling chickens. 
2.3.2 Cardiac morphology  
Right ventricular wall thickness and a myosin dense layer thickness were evaluated with 
H&E staining and immunohistochemistry for sarcomere myosin. Thinning of the right 
ventricular wall (corrected for whole heart weight) was observed in H&E stained tissues from the 
1 mg/kg and 2 mg/kg dose groups relative to vehicle controls (Figure 2.2A). The 1 mg/kg and 2 
mg/kg dose groups were 20.2% and 22.7% thinner, respectively, relative to vehicle controls (P < 
0.05). Staining of the myosin dense layer revealed thinning of the myosin dense layer in the right 
ventricular wall in  the 1 mg/kg and 2 mg/kg dose groups relative to vehicle controls (Figure 
2.2B). The 1 mg/kg and 2 mg/kg groups were 27.1% and 28.6% thinner, respectively, relative to 
vehicle controls (P < 0.05). 
2.3.3 Cardiac ultrasound 
 All morphological parameters evaluated by cardiac ultrasound demonstrated statistical 
significance relative to vehicle controls. The left ventricular posterior wall dimension at diastole 
(Figure 2.3A) increased by 5.7% (0.5 mg/kg), 29.6% (1 mg/kg), and 71.6% (2 mg/kg). The left 
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ventricular posterior wall dimension at systole (Figure 2.3B) was increased 4.9% (0.5 mg/kg), 
11.5% (1 mg/kg), and 26.0% (2 mg/kg). Left ventricular volume at diastole (Figure 2.3C) was 
increased by 6.7% (0.5 mg/kg) and decreased by 14.1% (1 mg/kg) and 40.4% (2 mg/kg). At 
systole, left ventricular volume (Figure 2.3D) was decreased by 12.2% (0.5 mg/kg), 48.5% (1 
mg/kg), and 76.0% (2 mg/kg). Finally, left ventricle mass (Figure 2.3E) was increased by 5.4% 
(0.5 mg/kg), 8.8% (1 mg/kg), and 24.7% (2 mg/kg). Left ventricular mass was the only 
morphological parameter that differed statistically between uninjected controls and vehicle 
controls; the mass of the vehicle controls was 5.1% greater than in uninjected controls. No other 
morphological differences were observed between uninjected controls and vehicle controls. 
Functional parameters collected by cardiac ultrasound also were statistically significant. 
Heart rate (Figure 2.4A) was decreased by 7.9% (0.5 mg/kg) and increased by 55.3% (1 mg/kg) 
and 52.9% (2 mg/kg). Stroke volume (Figure 2.4B) was elevated in the 0.5 mg/kg group (12.6%) 
and decreased in the 1 mg/kg group (3.4%) and 2 mg/kg group (29.5%). The ejection fraction 
(Figure 2.4C) was elevated by 5.4% (0.5 mg/kg), 9.0% (1 mg/kg), and 17.0% (2 mg/kg). 
Fraction shortening (Figure 2.4D) was elevated by 6.3% (0.5 mg/kg), 12.6% (1 mg/kg), and 
30.0% (2 mg/kg). No functional differences were observed between uninjected controls and 
vehicle controls. 
2.3.4 Cardiac myofibril ATPase 
An increased ratio of calcium-independent ATPase activity to calcium-dependent 
ATPase activity was observed, but the difference was not statistically significant (Figure 2.5). 
2.3.5 Serum concentration of PFOA 
Mean serum concentrations of PFOA in vehicle controls and uninjected controls were 
below limits of quantitation (LOQ) of 50 ng/mL. Mean PFOA serum concentrations in dosed 
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hatchlings (mean ± standard deviation) were 1230.8 ± 363.9, 2055.7 ± 1577.5, and 5670.0 ± 
3394.1 ng/mL for the 0.5, 1, and 2 mg/kg dose groups, respectively (Figure 2.6). Quality control 
standards were all within acceptable parameters, with coefficients of variation of less than 5%. 
 
2.4 Discussion 
From our observations, developmental exposure to PFOA in an avian model leads to 
alteration of heart morphology and function, which are effects similar to those observed in 
human congenital heart diseases as well as generalized cardiovascular diseases. Cardiac 
alterations were observed at doses that did not increase mortality or other markers of generalized 
toxicity in either D19 chicken embryos or hatchling chickens (Table 1). Cardiovascular diseases 
are a major concern to human health and the complexity of their etiology prevents them from 
being fully understood and therefore prevented. Congenital heart disease is the most prevalent 
cause of infant death resulting from birth defects, contributing to more than 24% of total infant 
mortality due to birth defects (Roger et al. 2011). The establishment of the primary heart tube, 
looping of the developing heart to the right, and septation to form a four-chamber heart are under 
the control of multiple signaling pathways. Exogenous agents are capable of disrupting these 
processes to alter heart development, resulting in malformation. Even if disruption in 
development does not directly lead to heart malformation, the effects of delayed development or 
altered function could still contribute significantly to heart diseases later in life. Previous studies 
report that developmental delays and subsequent catch up in development could increase the 
incidence of coronary heart disease, obesity, hypertension and type II diabetes (Langley-Evans, 
2006 and Eriksson, 2006). PFOA is capable of mimicking endogenous ligands and blocking or 
activating certain receptors, which are known to include PPAR , retinoid X receptor (RXR), and 
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other receptors in the steroid hormone receptor superfamily (DeWitt et al. 2009). PPAR  is 
known to be involved in heart development (Steinmetz et al. 2005). Moreover, we cannot 
eliminate the possibility of other unknown interactions of PFOA with other endogenous ligands. 
Thus, PFOA is potentially capable of disrupting signaling pathways in heart development and 
inducing developmental cardiotoxicity by its putative interaction with PPAR .  
Cardiac remodeling is an important factor in cardiovascular diseases. Normal ventricle 
wall thickness is a prerequisite to normal cardiac function. Thickening, thinning, or stiffening of 
ventricular walls could lead to disturbances in electricity-contraction coupling, induce ischemia 
and affect hemodynamics, contributing to hypertension (Dukanović et al. 2009). Hypertrophy is 
observed in many cardiovascular diseases, such as hypertrophic cardiomyopathy (Olivotto et al. 
2009), hypertensive heart (Koren et al. 1991) and congenital heart diseases (Buchhorn et al. 
2003). All of these diseases are reported to have ventricle dimension and ventricle mass 
alterations. In our study, similar alterations of cardiac morphology were observed: 
histopathology demonstrated that the right ventricular wall, especially the layer of dense myosin 
staining, was affected by developmental exposure to PFOA. Echocardiography showed increased 
left ventricle dimension and mass, which looked like an early stage hypertensive heart (Koren et 
al. 1991) even though the relative heart weight remained unchanged; perhaps the thinner wall 
observed in the right ventricle counterbalanced the increase in the left ventricle mass. Although, 
it is unknown if these alterations were due to primary alteration of the contractile machinery or 
secondary to volume/pressure overloading; the similarity between human diseases and our 
observations in experimental animals suggests the possibility that developmental PFOA exposure 
might contribute to human cardiovascular diseases, especially congenital heart diseases and/or 
later cardiovascular diseases including hypertensive heart and cardiomyopathy. However, no 
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conclusions about the effects of PFOA on cardiac development in humans can be made until a 
mechanism and its applicability to humans is determined.  
Cardiac ultrasound allowed us to directly measure cardiac functional parameters, 
including heart rate, stroke volume, ejection fraction(fraction of blood pumped out of the right 
and left ventricles with each heart beat) and fraction shortening (the fraction of any diastolic 
dimension that is lost in systole). These parameters are important indicators for congenital heart 
diseases as well as generalized cardiovascular diseases. Neonates with congenital heart disease 
often have altered heart rate, stroke volume, ejection fraction and fraction of shortening, which 
are diagnostic tools as well as indicators for treatments (Tsai et al. 2008, Beaufort-Krol et al. 
2007 and Lutin et al. 1999). In our study, we found significant alterations of these functional 
parameters: heart rate was slightly decreased by 0.5 mg/kg of PFOA and increased by over 50% 
relative to vehicle control in the 1 and 2 mg/kg groups. Stroke volume changes were in the 
opposite direction: relative to vehicle controls, it was slightly higher at 0.5 mg/kg and lower at 
the two higher doses. Overall, cardiac output was roughly the same as the vehicle control at all 
dose groups except for the 1 mg/kg group, which was elevated by 49.9% (data not shown). 
Meanwhile, ejection fraction and fraction shortening were elevated in all dosed groups, which 
are consistent with compensatory hypertrophy. Increased left ventricular mass and heart rate are 
consistent with decreased stroke volume in these animals. Compensation also could possibly 
explain the thinned right ventricular wall. Increased left ventricular pressure could decrease the 
blood shunt from pulmonary circulation to main circulation and thus cause volume overload in 
the right ventricle and a thinning of the right ventricular wall. One factor that we did not 
measure, but that could have impacted the functional parameters, is a PFOA-induced stress 
response. As we did not measure serum corticosterone levels in this study, we cannot speculate 
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about this potential contributor to our results. In future studies, we plan to evaluate cardiac 
function in adult chickens exposed during development to determine if the dysfunction persists 
or worsens after heat or exercise-induced stress. However, some toxicological endpoints 
associated with PFOA exposure, notably immune suppression, do not appear to be stress related 
(DeWitt et al. 2009). In general, ultrasound data suggest a dose-dependent PFOA-induced 
ventricular hypertrophy, which is well compensated at one day post-hatch. 
Myofibril consists of the whole contractility machinery in the myocardium. Its rate of 
ATP hydrolysis, i.e., myofibril ATPase activity, is an estimation of cardiac sarcomere function 
(Lionne et al. 2003) and can be an endpoint of cardiotoxicity (Cappelli et al. 1989). Calcium is 
an important regulator for myofibril ATPase activity and in disease conditions such as 
cardiomyopathy, calcium sensitivity can be altered, which ultimately affects myofibril ATPase 
activity (Chang et al. 2005). In our study, the cardiac myofibril ATPase assay demonstrated that 
the calcium-dependent ATPase activity did not differ across dose groups, but the calcium-
independent ATPase activity increased with the dose of PFOA, thus the ratio of calcium-
independent ATPase activity to calcium-dependent ATPase activity increased, (Figure 5). During 
cardiac hypertrophy, a compensatory mechanism is a reversion to the fetal phenotype and a 
decrease in myofibril ATPase activity. We observed the opposite, which suggests that in addition 
to inducing cardiac hypertrophy, developmental PFOA exposure also may affect cardiac 
energetics. Further investigation is warranted to determine how these events are related. 
Our data indicate that developmental exposure to PFOA affects morphology and function 
of the hearts of hatchling chickens. The similar morphological and functional changes between 
our avian model and human congenital heart disease as well as generalized cardiovascular 
diseases suggest that PFOA may have a similar mode or mechanism of action across vertebrate 
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phylogenetic classes; however, additional work is needed to investigate the mechanism of this 
endpoint before we can make conclusions about the direct relevancy of our findings to PFOA-
exposed humans. However, the observation of left ventricle structure via echocardiography 
showed structural changes similar to an early stage hypertensive heart; as a result, we cannot 
eliminate the possibility that PFOA’s effect on the heart is secondary to hemodynamic change. 
Future studies may include assessments of blood pressure. In addition, evaluating adult animals 
exposed to PFOA during development may provide more detailed information about the 
developmental basis of adult cardiovascular disease. 
As the result of the stewardship program between major fluorochemical manufacturers 
and the US EPA, PFOA is being phased out by its major U.S. manufacturers. Recent 
epidemiologic studies have reported that the geometric mean concentration in the general U.S. 
population has dropped from 4.7 ng/mL in 2000-2001 (Olsen et al. 2003) to 3.44 ng/mL in 2006 
(Olsen et al. 2011). However, pockets of high serum concentrations still exist in the U.S. Serum 
concentrations as high as 88 ng/mL (median of 38.1 ng/mL) have been reported in serum of 
donated blood from males living in New York state (Kannan et al. 2004). Recently, Hoffman et 
al. (2011) reported a high concentration of 164.3 ng/mL (median of 75.7 ng/mL) in males from a 
community surrounding a fluoropolymer production facility (Hoffman et al. 2011). Occupational 
exposures lead to higher values; serum PFOA concentrations as high as 5,100 ng/mL have been 
reported (Olsen et al. 2007). 
Occupational serum concentrations of PFOA can be four times greater than the serum 
concentration of the lowest dose group in the present study (1230.8 ng/ml), which suggests  
that if developing humans are exposed to occupational concentrations of PFOA, a risk of heart 
anomalies may exist. The serum concentration of PFOA in the low dose group of the present 
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study is only 14 times greater than the concentration reported for humans with high background 
concentrations (88 ng/mL) and about 7.5 times greater than the high concentration reported for 
the population living near a fluoropolymer production facility. This value suggests that 
developmental cardiotoxicity may be an endpoint of concern for highly exposed (non-
occupational) human populations, especially when combined with other risk factors. In a review 
of epidemiological studies evaluating the health effects of PFOA, Steenland et al. (2010) 
examined data on cardiovascular disease of workers exposed to PFOA. One study indicated a 
positive trend between serum PFOA and cardiovascular disease-associated mortality whereas 
another study indicated no positive trend. Steenland et al. (2010) concluded that data are 
currently insufficient for inferring associations between PFOA exposure and cardiovascular 
disease. However, the workers in the studies examined by Steenland et al. (2010) were likely 
adults during their exposure period. A lack of effects observed in studies of occupationally-
exposed adults cannot be taken to mean that developing humans will respond similarly, 
especially when the increased sensitivity of developing systems relative to adult systems is 
considered.  
As PFOA is present in wild birds, it is also important to consider the implications of our 
findings on environmental health. The range of PFOA concentrations reported in wild birds is 
approximately 0.06 to 2 ng/mL (Martin et al. 2004; Bossi et al. 2005 and Falandysz et al. 2007). 
Generally, levels of PFOA in wild birds are an order of magnitude lower than perfluorooctane 
sulfonate (PFOS), another PFAA of environmental and human health concern. We observed 
functional effects in all exposure groups and morphological effects in the two highest dose 
groups. The average PFOA serum concentration that we observed in our lowest dose group 
(1230.8 ng/mL) is 2 x 10
4
 to approximately 600 times higher than reported concentrations in 
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wild birds. At current PFOA exposure levels, our study suggests that wild birds are not at risk of 
developing heart anomalies.  
Currently, we are evaluating potential mechanisms behind the effects that we described. 
PFOA is a known PPARα agonist; agonism of PPARα may regulate expression of proteins 
involved in fatty acid transport, catabolism, and energy homeostasis (Peters et al. 2005). In 
addition, as reported by Izumi et al. (2001), bone morphorgenic protein-2 (BMP-2) inhibits 
apoptosis in neonatal cardiac myocytes. Decreased apoptosis may be a pathway to the 
hypertrophy that we observed in the hatchling chicken hearts. As PPARα also was reported to 
interact with the BMP-SMAD pathway (Takano et al. 2011), it is possible that PFOA’s 
developmental cardiotoxicity is initiation through its interaction with PPARα and subsequent 
alteration of the BMP-SMAD pathway. However, it also is possible that PFOA directly interacts 
with the BMP-SMAD pathway independent of PPARα. Initial studies with WY-14643, a strong 
PPARα agonist, indicate that the latter pathway may be more likely than the former. Moreover, 
because serum/plasma concentrations of PFOS are higher in wild birds than are PFOA 
concentrations, we plan to repeat the ultrasound studies with chickens exposed to PFOS. 
 
2.5 Conclusions 
This study investigated morphological and functional changes in developing chicken 
hearts following PFOA exposure. A thinner myosin dense layer in the right ventricular wall was 
observed and a thickened left ventricular wall and increased left ventricular mass was observed 
by cardiac ultrasound. Alteration in cardiac function also was observed by ultrasound; the 
decreased stroke volume along with increased heart rate indicates early compensation for cardiac 
dysfunction. A cardiac myofibril ATPase assay detected an increase in the calcium-independent 
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ATPase to calcium-dependent ATPase ratio. Our findings suggest that at the doses we 
administered, PFOA disrupts avian heart development. 
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Figure 2.1 Morphological measurement methods.  
A: Hearts were cut at approximately 60% of length of heart from ventricular apex. Ruler shows 
the total length (mm). Transverse line shows position of actual cut. 
B: Position of measurements for right ventricular wall thickness (H&E staining). Seven 
measurements were made on each heart (indicated by radiating lines). Angle between each 
measurement line was 22.5°. Arrows show measurement points for one of the seven 
measurements.  
C: Position of measurements for whole right ventricular wall and myosin dense layer thickness. 
RV: right ventricle. LV: left ventricle. Between open arrows: total right ventricular wall 
thickness. Between closed arrows: myosin dense layer thickness.  
D-F: Anatomical marker for relatively constant position on heart sections. D shows a cut at about 
70% length of heart from apex. Arrow: marker, which is too long. E shows a cut at 60% length 
from apex. Arrow: marker, which is size used across all sections. F shows a cut at 50% length 
from apex; marker absent. 
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Figure 2.2 Right ventricular wall thickness in hearts of 19-day-old chicken embryos. Fertile 
chicken eggs were injected with 0, 0.5, 1 and 2 mg/kg PFOA and incubated to day 19; hearts 
were sectioned at 6 μm and stained with H&E (A) or for myosin (B). 
A: Right ventricular wall thickness corrected for whole heart weight (Uninjected group not 
shown, N=7-10, error bar represents standard error of mean (SEM)). 
B: Right ventricular wall myosin dense layer thickness corrected with whole heart weight 
(N=11-15, error bar represents SEM). 
*: significantly different from vehicle controls (P<0.05). 
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Figure 2.3 Cardiac ultrasound of structural parameters in hearts of one-day-old hatchling 
chickens. (N=9-12, error bar represents SEM). Fertile chicken eggs were injected with 0, 0.5, 1 
and 2 mg/kg PFOA and incubated until hatch. One-day-old hatchling chickens were assessed by 
echocardiography. 
A: Left ventricular posterior wall dimension at diastole. 
B: Left ventricular posterior wall dimension at systole. 
C: Left ventricle volume at diastole. 
D: Left ventricle volume at systole.  
E: Left ventricle mass. 
*: significantly different from vehicle controls (P<0.05). 
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Figure 2.4 Cardiac ultrasound of functional parameters in hearts of one-day-old hatchling 
chickens. (N=9-12, error bar represents SEM). Fertile chicken eggs were injected with 0, 0.5, 1 
and 2 mg/kg PFOA and incubated until hatch. One-day-old hatchling chickens were assessed by 
echocardiography. 
A: Heart rate. 
B: Stroke volume. 
C: Ejection fraction. 
D: Fraction shortening. 
*: Significantly different from vehicle controls (P<0.05). 
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Figure 2.5 Cardiac myofibril ATPase activity in hearts of one-day-old hatchling chickens. Ratio 
of cardiac myofibril calcium independent ATPase activity to calcium ATPase activity. (N=5 for 
uninjected group, 7-9 for other groups, error bar represents SEM). 
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Figure 2.6 Serum PFOA concentrations measured in one-day-old hatchling chickens. Limit of 
quantitation (LOQ) was 50 ng/mL. All samples from uninjected and vehicle groups were below 
LOQ and were reported as 0 in the graph (N=2-6, error bar represents SEM).  
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 Table 2.1 Developmental toxicity parameters in 19-day-old chicken embryos and hatchling 
chickens. 
 
D19 Embryos
a
 
 
Uninjected Vehicle 0.5 mg/kg 1 mg/kg 2 mg/kg 
YFBW
b
 32.30±3.50
c
 30.75±4.15 34.26±4.14 32.74±2.42 32.97±4.47 
Relative heart 
weight
d
 
0.0078±0.0014 0.0075±0.00053 0.0078±0.0014 0.0076±0.00037 0.0086±0.0012 
Relative liver 
weight
e
 
0.018±0.0030 0.017±0.0052 0.014±0.0044 0.016±0.0030 0.016±0.0022 
Mortality 11.4% 26.7% 25.6% 31.4% 46.9%
f
 
 
Hatchling
g
 
 
Uninjected Vehicle 0.5 mg/kg 1 mg/kg 2 mg/kg 
YFBW 36.32±4.45 35.66±2.69 34.51±3.55 35.79±2.50 37.25±4.90 
CR length 
(mm)
h
 
8.92±0.59 9.15±1.21 9.38±1.12 9.66±1.15 8.72±0.62 
Relative heart 
weight 
0.011±0.0011 0.011±0.0010 0.011±0.0013 0.011±0.00091 0.011±0.0013 
Relative liver 
weight 
0.024±0.0039 0.021±0.0052 0.027±0.0032
f
 0.027±0.0050
f
 0.025±0.0028 
Mortality
i
 22.2% 33.3% 45.5% 39.1% 37.5% 
Hatchability 83.3% 64.3% 64.3% 66.7% 58.3% 
a
 N = 6 to 9 per dose group. 
b
 Yolk-free body weight. 
c
 Mean ± standard derivation. 
d
 Relative heart weight = heart weight/YFBW. 
e 
 Relative liver weight = liver weight/YFBW. 
f
 Statistically different from vehicle control grouip (P < 0.05). 
g
 N = 26 for uninjected group and 9 to 12 for other groups. 
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h
 Crown to rump length. 
i Note that  mortality increased between D19 and hatching in the 0.5 mg/kg and 1 mg/kg groups. 
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CHAPTER 3 PERFLUROOCTANOIC ACID INDUCED DEVELOPMENTAL 
CARDIOTOXICITY: ARE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR α 
(PPARα) AND BOND MORPHORGENIC PROTEIN 2 (BMP2) PATHWAYS INVOLVED?  
 
Abstract 
Perfluorooctanoic acid (PFOA) is an environmental contaminant known to induce 
developmental toxicity in animal models through activation of the peroxisome proliferator 
activated receptor α (PPARα). Previously, it was demonstrated that in ovo exposure to PFOA 
induced cardiotoxicity in chicken embryos and hatchlings. To investigate potential PPARα-
mediated mechanisms, fertile chicken eggs were injected prior to incubation with WY 14,643, a 
PPARα agonist. Cardiac morphology and function were evaluated in late stage embryos and 
hatchlings. Histologically, unlike PFOA, WY 14,643 did not induce thinning of the right 
ventricular wall. Via echocardiography, however, WY 14,643 induced effects similar to PFOA, 
including increased left ventricular wall thickness and mass, elevated heart rate, ejection fraction, 
fractional shortening, and decreased stroke volume. Additionally, to investigate mechanisms 
associated with early heart development, a separate group of fertile chicken eggs was injected 
prior to incubation with PFOA or WY 14,643 and in early stage embryos, gene expression and 
protein concentration associated with the bone morphogenic protein (BMP2) pathway was 
determined. Although changes were not statistically consistent among doses, expression of 
BMP2, Nkx2.5, and GATA4 mRNA in early embryos was altered by PFOA exposure; however, 
protein concentrations of these targets were not markedly altered by either PFOA or WY 14,643. 
Protein levels of pSMAD1/5, a transcriptional regulator stimulated by BMPs, were altered by 
both PFOA and WY 14,643, but in different directions; PFOA reduced cytoplasmic pSMAD1/5 
In press with the Journal of Toxicology and Environmental Health, Part A. Jiang, Q., Lust, R.M. and DeWitt, J.C. 
Reprinted by permission of Taylor & Francis (www.tandfonline.com). 
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whereas WY 14,643 decreased nuclear pSMAD1/5. Taken together, these data suggest that 
developmental cardiotoxicity induced by PFOA likely involves both PPARα and BMP2 
pathways.  
 
3.1 Introduction 
Perfluorooctanoic acid (PFOA) is a fluorinated compound that is used as a 
polymerization aid in the manufacture of many fluorinated polymers and elastomers, which are 
then used in myriad consumer and industrial products. PFOA is persistent in environmental 
media (Vaalgamaa et al. 2011) and is detectable in biota as well as serum of the general human 
population. The median human serum concentration in the U.S. general population was 4.3 
ng/ml in 2007-2008 (CDC 2012). However, in areas with contaminated drinking water, serum 
concentrations are higher. Shin et al. (2011) reported a median serum value of 24.3 ng/ml in 
residents living in an area of high contamination in West Virginia and Ohio. Another study 
reported a median serum value of 75.7 ng/ml in residents of communities surrounding a 
fluoropolymer production facility (Hoffman et al. 2011). Serum concentrations as high as 5100 
ng/ml have been reported in occupationally-exposed humans (Olsen et al. 2007). Because of the 
persistence of PFOA and related compounds in environmental and human samples, the U.S. 
Environmental Protection Agency (USEPA) worked with 8 major manufacturers of PFOA to 
establish a stewardship program to eliminate PFOA and related compounds from emissions and 
products by 2015 (USEPA 2012). However, exposure likely will continue for a considerable 
time due to the environmental persistence and long half life of PFOA in humans.  
Epidemiological studies of the effects of PFOA on human development have been 
conducted in areas of known high exposures such as West Virginia-Ohio (U.S.) (Frisbee et al. 
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2009) and the Faroe Islands (Denmark) (Grandjean et al. 2012). Modest associations of PFOA 
serum concentrations with preeclampsia and birth defects were found in the Mid-Ohio Valley 
population (Stein et al. 2009). PFOA exposure was also associated with elevated serum 
cholesterol and uric acid levels in children and adolescents from this population (Frisbee et al. 
2010). However, Nolan et al. (2009; 2010) reported that elevated PFOA exposure in this 
population was not associated with lowered birth weight or gestational age, labor or delivery 
complications, or maternal risk factors such as eclampsia or diabetes, although lack of umbilical 
cord serum PFOA concentrations made it difficult to assess actual fetal exposures. In a recent 
study, developmental exposure to a mixture of perfluorinated compounds (PFCs) was associated 
with decreased responses to vaccinations in children between 5 and 7 years of age living in the 
Faroe Islands (Grandjean et al. 2012). In laboratory animal models, PFOA is known to induce 
hepatic, pancreatic, and testicular cell cancers (Biegel et al. 2001), endocrine disruption (Olsen et 
al. 1998), and immunotoxicity (DeWitt et al. 2008). In addition, PFOA was reported to induce 
developmental effects, including retarded development and decreased fetal survival (Wolf et al. 
2007). The mechanisms underlying retarded development and decreased fetal survival remain to 
be elucidated. It was postulated that as the cardiovascular system is one of the earliest organ 
systems to develop, cardiotoxicity induced by developmental PFOA exposure may contribute to 
decreased fetal survival. 
Previously, Jiang et al. (2012) observed developmental cardiotoxicity in an avian model. 
Following in ovo developmental exposure to PFOA, hearts from near-hatch (embryonic day 19; 
ED19) domestic chicken embryos exhibited morphological and functional changes, including 
thinning of the right ventricular wall and of a layer of dense myosin staining within the right 
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ventricular wall, increased left ventricle dimension, and altered left ventricular function. The 
underlying mechanism(s) of this developmental cardiotoxicity remain unknown.  
It is generally accepted that PFOA activates PPARα (Rosen et al. 2008). PPARα is a 
ligand-activated transcription factor in the steroid hormone superfamily that regulates fatty acid 
metabolism, a process that may induce several effects on cardiac tissue (Djouadi et al. 1999). To 
our knowledge, PPARα activation is not a major pathway or transcription factor involved 
specifically in heart development nor is its activation known to directly interfere with the major 
pathways associated with heart development. Regardless, evidence exists that PPARα activation 
has the potential to affect the cardiovascular system. Yuan et al. (2008) reported that PPARα 
activation attenuated myocardial damage induced by isoproterenol, a medication used to treat 
bradycardia, in adult Wistar rats. Another study indicated that mutation of the PPARα gene 
resulted in left ventricular diastolic dysfunction (Juang et al. 2010). It is possible that PPARα 
activation plays a role in the developmental cardiotoxicity induced by PFOA. However, not all 
toxicities induced by PFOA exposure require PPARα; PFOA-induced suppression of antigen-
specific antibody responses occured at similar doses in both wild-type and constitutive PPARα 
knock-out C57BL/6 mice (DeWitt et al. 2008). Therefore, the aim of this study was to explore 
the potential mechanisms underlying of PFOA-induced developmental cardiotoxicity in an avian 
model by examining pathways associated with PPARα agonism, pathways known to be 
associated with PFOA exposure, and pathways known to be critical for early heart development.  
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3.2 Methods and materials 
3.2.1 Overall methods 
3.2.1.1 Chemicals   
Sunflower oil was purchased from Spectrum Organic Products, LLC (Boulder, CO). 
PFOA, WY 14, 643, and other chemicals (if not otherwise mentioned) were purchased from 
Sigma–Aldrich (St. Louis, MO). 
3.2.1.2 Animals 
Fertile chicken (Gallus gallus) eggs were purchased from the North Carolina State 
University Poultry Research Center (Raleigh, NC). Eggs were cleaned with 20% povidone 
iodine, candled to outline air cells in pencil on shells, weighed, given ID numbers, and evenly 
distributed by weight among doses. Uninjected eggs were included in each batch as 
environmental controls. 
3.2.1.3 Egg injection and incubation 
Egg injection and incubation were carried out as described previously (Jiang et al. 2012). 
Briefly, PFOA or WY 14,643 was suspended in sunflower oil and vortexed before injection into 
the air cell of each egg. Ten percent ethanol was added to the WY 14,643 solutions to improve 
its solubility in oil. Stock solutions were prepared so that 0.1 µl of solution per g egg weight 
resulted in the appropriate mg/kg egg weight concentration. After injection, eggs were incubated 
in a Lyon Roll-X incubator (Chula Vista, CA) set at 37.5–37.8 ºC dry bulb and 30.6–31.1 ºC wet 
bulb. 
3.2.1.4 Sample collection for late stage embryos and hatchlings 
Eggs incubated until ED19 or hatch were candled every 2-3 days so that 
infertile/undeveloped/dead eggs could be removed. After external pipping, eggs were placed 
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individually into containers large enough for the hatched chickens and transferred to a larger 
incubator (G.Q.F. Manufacturing Co., Savannah, GA). Hatchling chickens were kept in a 
warmed brood box until euthanasia; all echocardiography measurements were collected on 
hatchlings within 24 hr of hatch. On ED19, chicken embryos were removed from eggs and 
quickly decapitated. Hearts were collected, rinsed in cold saline, weighed, and fixed in 
formaldehyde for histological analysis. Livers were collected, weighed, frozen on dry ice, and 
then stored at -80ºC for later use. Hatchling chickens were anesthetized with carbon dioxide and 
quickly decapitated. Serum, heart, and liver were collected and stored at -80ºC for later use. All 
procedures were approved by the East Carolina University Institutional Animal Care and Use 
Committee. 
3.2.1.5 Sample collection for early stage embryos  
Two groups of early stage embryos were collected; one group included whole embryos 
collected on ED4 and another group included isolated hearts from ED6 embryos. On ED4, whole 
embryos were removed from eggs, dissected to remove the amnionic membrane, snap frozen in 
liquid nitrogen, and then stored at -80ºC for later use. On ED6, whole embryos were removed 
from eggs; hearts were dissected out, snap frozen in liquid nitrogen, and then stored at -80ºC for 
later use.  
3.2.1.6 Statistical analysis     
All data are presented as mean ± standard deviation. Statistical analyses were performed 
with the SAS JMP System (SAS Institute, Cary, NC). Endpoints were analyzed by one-way 
analysis of variance (ANOVA) by dose and when ANOVA results indicated statistically 
significant dose effects, individual post hoc comparisons were made with a two-tailed t-test. 
Statistical significance was determined when P-values were less than 0.05. For the western blot 
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sample collection, samples were collected in two batches for whole embryos collected at ED4 
and another two batches for hearts collected from ED6 embryos due to size limitations of the egg 
incubator. These batches were statistically compared before pooling, which verified that the 
results of each batch did not differ statistically. 
3.2.2 Methods specific to PPARα agonism by WY 14,643 
The following section describes experiments done only with eggs injected with WY 
14,643 to investigate the role of PPARα agonism in developmental cardiotoxicity.  
3.2.2.1 Echocardiography on hatchling chickens 
Echocardiography was used to assess cardiac morphology and function in hatchling 
chickens exposed to WY 14,643. Briefly, hatchling chickens were evaluated with Vevo 2100 
(Visualsonics, Toronto, Ontario, Canada) within 24 hours post-hatch. Hatchlings were enclosed 
in stockinettes for proper restraint without feather damage. A hole was cut on the stockinette to 
expose the chest so that echocardiography could be carried out. For detailed procedures please 
refer to Jiang et al. (2012).  
3.2.2.2 Histology    
Histology on hearts from ED19 chickens treated with vehicle or WY 14,643 was carried 
out as previously described (Jiang et al. 2012). Briefly, ventricles were paraffin embedded and 
sliced into 6 µ sections on a rotary microtome. One subset of the sections was stained with 
hematoxylin and eosin for morphological measurement of the thickness of the right ventricular 
wall. Another subset of the sections was stained immunohistochemically with myosin for 
measurement of the thickness of a dense layer of myosin staining present in the right ventricular 
wall. Figure 3.1A illustrates the right ventricular wall thickness and the thickness of a dense 
layer of myosin staining.  
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3.2.2.3 Quantitative real-time PCR     
Livers from hatchling chickens were assessed with quantitative real-time PCR for 
expression of liver fatty-acid-binding protein (L-FABP), a transcript indicative of PPARα 
activation that can be used to confirm exposure of WY 14,643 to embryos (Karam and 
Ghanayem, 1997). While the CYP4A family genes are more commonly used as PPARα 
activation confirmation in rodents, avian species do not express CYP4A. RNeasy Mini Kits, 
QuantiTect Reverse-Transcription Kit, SYBR green, and primers were purchased from Qiagen 
(Valencia, CA). RNAspin Mini Kits were purchased from GE Healthcare (Little Chalfont, UK) 
and Total RNA mini kits were purchased from IBI scientific (Peosta, IA). Additionally, SYBR 
green mastermix and iScript Advanced cDNA Synthesis Kits were purchased from Bio-Rad 
Laboratories (Hercules, CA). RNA isolation was carried out according to manufacturer’s 
protocols. A Nanodrop ND-1000 (Wilmington, DE) was used to determine the concentration and 
quality of mRNA. For reverse transcription, manufacturer’s protocols were followed and 1 µg 
mRNA used for each sample. Quantitative real-time PCR was carried out in 25 µl (Qiagen 
SYBR Green) or 20 µl (Bio-Rad SYBR Green). The PCR reactions were performed in an 
Applied Biosystems StepOne Plus (Foster City, CA) or Bio-Rad CFX96 Real-Time PCR 
machine (Hercules, CA). Results were analyzed with the two delta-delta-CT method, 
normalizing to GAPDH for fold changes relative to the vehicle control group.  
3.2.2.4 Western blot    
Early stage embryos exposed to WY 14,643 were analyzed with western blot to measure 
levels of pSMAD1/5 (in ED4 whole embryos), Nkx2.5, and pGATA4 proteins (in ED6 hearts). 
Cytoplasmic and nuclear proteins from whole ED4 embryos were separated with an NXTRACT 
kit, with the addition of 25mM beta-glycerophosphate. Hearts isolated from ED6 embryos were 
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homogenized in RIPA buffer (sodium chloride 150 mM, Tris-HCl 50 mM, SDS 0.1%, sodium 
deoxycholate 0.5% and triton X-100 1%) with 0.5 mM dithiothreitol (DTT), 25mM beta-
glycerophosphate, and 1:100 protease inhibitor cocktail (Thermo Scientific, Rockford, IL), 
extracted in a cold room (4°C) for 2 hr and then centrifuged at 15000xg for 10 min. Primary 
antibodies included anti pSMAD1/5 (Invitrogen, Grand Island, NY), anti nkx2.5 (Abcam, 
Cambridge, MA), and anti pGATA4 (Invitrogen, Grand Island, NY), all applied at 1:1000; anti-
beta actin was applied at 1:10000. Secondary antibodies (LI-COR Biosciences, Lincoln, NE) 
were all applied at 1:15000. Visualization and semi-quantification was conducted with a LI-COR 
Odyssey system (LI-COR Biosciences, Lincoln, NE), all target proteins were normalized to beta 
actin and compared to vehicle control for relative fold change.  
3.2.3 Methods specific to PFOA-exposed embryos 
The following section describes experiments conducted with eggs only injected with 
PFOA to investigate the role of pathways associated not only with potential PPARα agonism by 
PFOA, but pathways associated with PFOA exposure and early heart development. These 
pathways included inflammatory cytokines and BMP2-pSMAD1/5-Nkx2.5/GATA4 pathways.  
3.2.3.1 Quantitative real-time PCR     
Early stage embryo samples (ED4 whole embryos and hearts isolated from ED6 
embryos) were assessed with quantitative real-time PCR for expression of various genes 
following PFOA exposure. Reagents and methods used were the same as described in the 
previous section. Targets included GAPDH, PPARα, BMPR1A, LITAF, IL1-β, IL-6, BMP2, 
RXRα, Nkx2.5 and GATA4.    
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3.2.3.2 Western blot    
Proteins isolated from early stage embryo samples exposed to PFOA were analyzed with 
western blot to measure levels of pSMAD1/5 (in ED4 whole embryos), Nkx2.5, and pGATA4 
proteins (in ED6 hearts). Reagents and methods were the same as described in the previous 
section. 
 
3.3 Results 
3.3.1 PPARα agonism by WY 14,643 
3.3.1.1 General toxicity  
Mortality, hatchability, yolk-free body weight, absolute heart weight, and relative heart 
and liver weights for both ED19 embryos and hatchling chickens following exposure to WY 
14,643 are reported in Table 3.1. In ED19 embryos, no significant changes were observed among 
the parameters measured. In hatchling chickens exposed to 25 mg of WY 14,643/kg egg weight, 
relative heart weight was significantly elevated by 18.3% relative to the vehicle group. No other 
differences in general toxicity parameters were observed. 
3.3.1.2 Histology  
In ovo exposure to WY 14,643 did not induce a thinning of the right ventricular wall or 
of a dense layer of myosin staining in the right ventricular wall of ED19 chicken embryos. 
Representative histology sections are shown in Figures 3.1B, C and D. As illustrated in Figures 
3.1E and 1F, no marked differences among dose groups were detected.  
3.3.1.3 Echocardiography     
Echocardiography revealed morphological and functional alterations in hearts of 
hatchling chickens exposed to WY 14,643 during development, relative to hearts of vehicle-
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exposed hatchlings. As shown in Table 3.2, exposure to WY 14,643 increased left ventricular 
posterior wall dimension at diastole by 21.4% (5 mg/kg egg weight) and 96.7% (25 mg/kg egg 
weight). At systole, exposure to WY 14,643 elevated left ventricular posterior wall dimension by 
20.8% (5 mg/kg egg weight) and 44% (25 mg/kg egg weight). The volume of the left ventricular 
volume was reduced by 13.8% (5 mg/kg egg weight) and 36.4% (25 mg/kg egg weight) at 
diastole. At systole, left ventricular volume was decreased by 45.8% (5 mg/kg egg weight) and 
72.3% (25 mg/kg egg weight). In addition, left ventricle mass was increased by 23.9% (5 mg/kg 
egg weight) and 44.4% (25 mg/kg egg weight).  
Exposure to WY 14,643 also affected how the hearts of the hatchling chickens 
functioned. Heart rate was elevated by 48.1% (5 mg/kg egg weight) and 59.8% (25 mg/kg egg 
weight) and stroke volume was reduced in the 25 mg/kg egg weight group (26.1%). Cardiac 
output was elevated by 63.2% (5 mg/kg egg weight) and 85.0% (25 mg/kg egg weight). The 
ejection fraction was elevated by 10.3% (5 mg/kg egg weight) and 15.8% (25 mg/kg egg 
weight). Fractional shortening was increased by 6.2% (25 mg/kg egg weight). 
3.3.1.4 Quantitative real-time PCR 
In livers of hatchling chickens exposed to WY 14,643, L-FABP mRNA was significantly 
increased by 87.1% following exposure to 25 mg/kg egg weight (Figure 3.2) but not by 5 mg/kg 
egg weight. Further, in a subset of livers collected from hatchling chickens exposed to 2 mg/kg 
egg weight of PFOA, L-FABP was not markedly elevated. 
3.3.1.5 Western blot     
In protein extracted from ED4 whole embryos exposed to WY 14,643, the nuclear 
pSMAD1/5 level was significantly decreased by 22.2%, on average (Figure 3.3D). No marked 
difference was detected in cytoplasmic levels of pSMAD1/5 (Figure 3.3C). No significant 
 57 
 
differences were detected in levels of Nkx2.5 (Figure 3.5A) or pGATA4 (Figure 3.5B) proteins 
when hearts of ED6 embryos were examined. 
3.3.2 PFOA-exposed embryos 
3.3.2.1 Quantitative real-time PCR    
Exposure to PFOA did not markedly alter expression of PPARα, BMPR1A, LITAF, IL1-
β, IL-6 and RXRα mRNA in ED4 whole embryos (data not shown). BMP2 (Figure 3.4A) was 
significantly decreased by 31.9% in embryos treated with 0.5 mg/kg egg weight relative to 
vehicle control, but not in any other dose group or in hearts collected from ED6 embryos. 
Following PFOA exposure, expression of Nkx2.5 (Figure 3.4B) and GATA4 (Figure 3.4C) 
mRNA was significantly elevated in hearts collected from ED6 embryos. Nkx2.5 was increased 
by 60.7% after exposure to 2 mg/kg egg weight; GATA4 was elevated by 78%, on average, after 
exposure to all doses of PFOA. 
3.3.2.2 Western blot     
In protein extracted from ED4 whole embryos exposed to PFOA, cytoplasmic levels of 
pSMAD1/5 were significantly decreased by an average of 32.5% after exposure to 1 or 2 mg/kg 
egg weight (Figure 3.3A). No marked difference was detected in nuclear levels of pSMAD1/5 
(Figure 3.3B). No marked differences were detected in levels of Nkx2.5 (Figure 3.5A) or 
pGATA4 (Figure 3.5B) proteins when hearts of ED6 embryos were examined. 
 
3.4 Discussion 
3.4.1 Dose selection 
Dose selection for PFOA was based on observations by O’Brien et al. (2009) that up to 
10 mg of a PFOA injection/kg of egg weight did not affect pipping success and on previous 
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experiments done in our lab. From our previous study (Jiang et al. 2012), air cell injection of 2 
mg of PFOA/kg of egg weight prior to incubation resulted in serum concentrations of 5670 
ng/ml in hatchling chickens, which is higher levels in the general human population but 
comparable to levels in occupationally- exposed humans. Dose selection for WY 14,643 was 
based on a study by Woods et al. (2007) and on pilot studies in our lab. Woods et al. (2007) gave 
WY 14,643 by oral gavage to C57B6/J and SV129 mice at 5 mg/kg and 50 mg/kg without acute 
complications, and observed significant increases in downstream genes regulated by PPARα 
activation, including Acyl-CoA oxidase. In the current study, the doses applied 0, 5 or 25 mg of 
WY 14,643/kg egg weight did not increase mortality and 25 mg/kg was the highest achievable 
dose for this procedure, based on the solubility of WY 14,643 in oil. Note that as WY 14,643 is 
metabolized during development, it is impossible to obtain accurate serum concentrations in 
hatchling chickens for comparisons to PFOA serum concentrations.  
3.4.2 Comparison between WY 14,643 and PFOA on PPARα activation 
WY 14,643 is a PPARα agonist; as low as 0.3 mg/kg will fully activate PPARα in the 
mouse, but about 18 mg/kg is needed to fully activate PPARα in humans (Maloney and 
Waxman, 1999). The high dose of WY 14,643 applied (25 mg/kg) was designed to activate 
PPARα to the maximum extent without inducing marked embryonic mortality. mRNA 
expression of L-FABP confirmed that PPARα was activated sufficiently following exposure to 
25 mg/kg of WY 14,643. PFOA has a lower affinity for PPARα. And at least 2-4 mg/kg is 
needed to fully activate the mouse PPARα (Maloney and Waxman, 1999). No published data 
have elaborated the ability of WY 14,643 or PFOA to activate the avian isoform of PPARα. 
From a previous pilot study in our lab, Acyl CoA oxidase activity did not increase in livers 
isolated from chicken embryos of various ages exposed to 0, 0.5, 1, or 2 mg of PFOA/kg of egg 
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weight prior to the start of incubation (data not shown). These pilot data suggest limited PPARα 
activation in chickens. However, 2 mg/kg of egg weight was the highest PFOA dose in this 
procedure that did not significantly induce mortality and general toxicity. This dose of PFOA did 
increase mean L-FABP mRNA expression (although not markedly), indicating mild PPARα 
activation by PFOA. However, as doses of PFOA greater than 2 mg/kg induce embryonic 
mortality and general toxicity, as demonstrated by our previous studies (Jiang et al. 2012), it is 
likely that PPARα activation by PFOA is not a major mechanism of embryonic mortality in a 
chicken model. 
3.4.3 PPARα agonism and developmental cardiotoxicity 
The role of PPARα agonism in developmental cardiotoxicity was investigated by using 
the PPARα agonist WY 14,643. Numerous studies have reported effects of WY 14,643 exposure 
on the heart, including inhibition of mitochondrial respiration in isolated rat cardiac 
mitochondria (Zungu et al. 2006), altered fatty acid composition of myocardial lipids 
(Baranowski et al. 2009), and attenuation of cardiomyocytic apoptosis following cardiac 
ischemia and reperfusion (Yeh et al. 2006). Developmental exposure to WY 14,643 did not 
increase the mortality rate in ED19 chicken embryos or hatchling chickens. Developmental 
exposure to PFOA, however, elevated the mortality rate in ED19 chicken embryos at the highest 
dose administered (2 mg of PFOA/kg of egg weight), but not in hatchling chickens (Jiang et al. 
2012). The difference in mortality between PFOA and WY 14,643 in chicken embryos and 
hatchlings suggests that developmental toxicity of PFOA, in an avian model, is not fully 
dependent on PPARα agonism. In mammalian models, certain developmental endpoints affected 
by PFOA exposure require expression of PPARα (Abbott et al. 2007). However, not all measures 
of PFOA-induced developmental toxicity in mammalian models may be dependent on PPARα 
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agonism as activation of PPARα by WY 14,643 did not affect developmental toxicity in a mouse 
model (Palkar et al. 2010). Changes in expression of PPARα in early stage embryos following 
PFOA exposure were not noted. 
Developmental exposure to WY 14,643 did not induce detectable histological thinning of 
the right ventricular wall (Figure 1) in hearts from ED19 chicken embryos, while developmental 
PFOA exposure did (Jiang et al. 2012). However, echocardiography demonstrated that 
developmental exposure to WY 14,643 induced effects similar to PFOA (Jiang et al. 2012). One 
such effect was an enlarged left ventricle and higher-than-normal functional parameters, which 
are indicative of morphological and functional alterations observed in a compensating 
hypertensive heart. Previously, it was postulated that the thinned right ventricular wall resulted 
from enlargement of the left ventricle, possibly from elevated circulation pressure. This also may 
be the case after exposure to WY 14,643, although the effects were not sufficiently pronounced 
to be detectable histologically, suggesting that agonism of PPARα may play an important, but 
not singular, role in developmental cardiotoxicity observed in chicken embryos and hatchlings 
exposed to PFOA. mRNA levels of L-FABP were higher in WY 14,643 exposed than in PFOA 
exposed embryos (Figure 2), indicating that WY 14,643 more potently activates PPARα in 
avians than does PFOA at the doses applied. Therefore, other pathways and/or processes, in 
addition to PPARα activation, likely contribute to cardiac changes noted in PFOA-exposed avian 
embryos. 
3.4.4 Other pathways to PFOA-induced developmental cardiotoxicity 
While the experiments with WY 14,643 suggest a role for PPARα agonism in 
developmental cardiotoxicity, exposure to WY 14,643 did not completely mimic the effects of 
PFOA. Therefore, additional pathways, including those independent of PPARα, likely exist.  
 61 
 
3.4.4.1 Inflammatory cytokines 
While PPARα activation is not among the classical pathways involved in heart 
development (Kirby 2002), such as activin/TGF-beta and BMP-2/BMP-4 (Ladd et al. 1998), 
FGF family (Zhu et al. 1996), Nkx2.5 (Schultheiss et al. 1995), GATA4 (Charron and Nemer 
1999) and MEF-2 (Black and Olson 1998), PFOA affects expression of inflammatory cytokines 
(DeWitt et al. 2009). However, there are contradictory reports regarding the effects of PFOA on 
inflammatory cytokines. While Taylor et al. (2005) reported that PFOA has potency similar to 
dexamethasone, a known anti-inflammatory agent, against carageenan-induced edema and 
thermal hypersensitivity, Yang (2010) found that PFOA exposure increased expression of 
various inflammatory cytokines in Japanese medaka. The induction/suppression of inflammatory 
cytokine production may potentially contribute to the developmental cardiotoxicity observed 
with PFOA. Inflammatory cytokines might interfere with signaling pathways that are important 
to heart development. IL-1β  was found to be able to modulate TGF-beta signaling via IL-6 
activation (Luo et al. 2009) and increased TNF-alpha could suppress the TGF-beta receptor 
population (Yamane et al. 2003). TGF-beta superfamily signaling pathways are crucial for heart 
development; induction in inflammatory cytokines might contribute to development 
cardiotoxicity induced by PFOA. While a difference in mRNA expression was not detected for 
the inflammatory cytokines in early stage embryos, one cannot discount disruption of 
inflammatory pathways as a contributory factor in PFOA-induced developmental cardiotoxicity. 
Only limited information is available for early chicken embryo cytokine expression profile. 
Meade et al. (2009) reported IL-1β expression decreased from ED3 to ED9, then rose to 
comparable levels to ED3 after ED10. The rapid change of IL-1β and possibly expression of 
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other cytokines in early chicken embryo development may have prevented detection of changes 
induced by PFOA exposure.  
3.4.4.2 Bone morphogenetic protein 2 
BMP2 mRNA was decreased at the lowest administered dose of PFOA in whole embryos 
collected at ED4, indicating that BMP2 may be involved in PFOA-induced developmental 
cardiotoxicity. This alteration was not observed in hearts isolated from ED6 embryos, suggesting 
that interference with BMP2 may occur outside of the heart proper and that the expression of 
BMP2 is likely dynamic, and possibly transient, similar to observations in the mouse embryo 
cranial base, where BMP2 mRNA expression area and levels constantly changed from ED10 to 
postnatal day 5 (Kettunen et al. 2006). Although alterations of ligand expression by itself are not 
sufficient to conclude that a particular signaling pathway contributes to a specific endpoint, 
further evidence from the western blot for pSMAD1/5, the activated form of second messengers 
in the BMP2 pathway, suggests that this pathway may be affected by PFOA exposure. SMAD 
are second messengers that normally exist in the cytoplasm. On activation, they are 
phosphorylated, form polymers, and enter the nucleus to as act as transcription factors. By 
separating the cytoplasmic from the nuclear proteins, additional information about second 
messenger activation and nuclear trafficking was revealed. Interestingly, PFOA and WY 14,643 
induced differential responses for pSMAD1/5. WY 14,643 is known to be a full PPARα agonist, 
the decreased nuclear pSMAD1/5 concentration suggests that PPARα activation affects the 
BMP2-SMAD1/5 pathway and potentially decreased the amount of available heteromeric SMAD 
complex in the nucleus. However, PFOA did not affect the nuclear pSMAD1/5; instead, it 
decreased the amount of cytoplasmic pSMAD1/5, potentially decreasing the available second 
messenger pool. The differential effects could be due to different affinity for PPARα and thus a 
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different extent of PPARα activation or that PPARα-independent mechanisms also contribute to 
the effect induced by PFOA. These data therefore provide evidence that the BMP2-SMAD1/5 
pathway is involved in PFOA-induced developmental cardiotoxicity because altered BMP2 
expression and second messenger levels following PFOA exposure were observed. The precise 
time where PFOA interferes with this signaling pathway remains unknown.   
The BMP2 signaling pathway induces both Nkx2.5 and GATA4 expression in developing 
embryos (Barron et al. 2000). Nkx2.5 is a transcription factor that plays important roles in the 
regulation of cardiac development, including early specification and proliferation of cardiac 
precursors and later events such as the formation of the outflow tract (McCulley et al. 2012; 
Harvey et al. 2002). GATA4 is another transcription factor that is crucial in cardiac 
morphogenesis and cardiomyocyte proliferation. Decreased GATA4 expression could lead to 
common atrioventricular canal (CAVC), double outlet right ventricle (DORV), and hypoplastic 
ventricular myocardium (Pu et al. 2004). Loss of Nkx2.5 and GATA4 lead to heart malformation 
and lethality (Tanaka et al. 1999; Kuo et al. 1997). In the current study, elevated expression of 
Nkx2.5 and GATA4 mRNA, but not protein levels, was observed in hearts isolated from ED6 
embryos exposed to PFOA during this early stage of development. This is additional evidence 
that the BMP2-SMAD pathway may be involved in developmental cardiotoxicity induced by 
PFOA. Nkx2.5 and GATA4 exert hypertrophic effects when upregulated (Li et al. 2011). Higher 
mRNA expression of Nkx2.5 and GATA4 may partially contribute to the left ventricular 
hypertrophy and/or the right ventricular wall thinning noted. However PFOA exposure did not 
markedly alter Nkx2.5 or phosphorylated GATA4 (S105) (pGATA4, the activated form of 
GATA4) protein levels. Perhaps potential differential expression levels of protein and mRNA or 
fast degradation/turnover of protein prevented detection of the difference. One possible 
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explanation for the lack of difference in GATA4 protein concentration may be that 
phosphorylated GATA4 remains the same whereas the GATA4 pool is changed. However, this 
remains untested based on antibody availability for an avian model. 
Our findings indicate that the BMP2-SMAD1/5-Nkx2.5 and GATA4 signaling pathways 
are altered by developmental PFOA exposure. These pathways therefore may be involved in 
PFOA-induced developmental cardiotoxicity in an avian model. However, additional studies are 
required to further elucidate the precise role of PPARα, BMP2 and Nkx2.5/GATA4 in this 
developmental cardiotoxicity.   
3.4.4.3 Interaction between PPARα and other pathways 
The current study illustrated that multiple pathways may contribute to PFOA-induced 
developmental cardiotoxicity. Data from WY 14,643 experiments indicated that PPARα is one of 
the pathways that likely contributes to the cardiotoxicity, but because WY 14,643 did not fully 
mimic the effects of PFOA, other pathways likely exist. Furthermore, alterations in the BMP2 
ligand, second messenger, and downstream genes were observed following PFOA exposure, 
suggesting that BMP2-SMAD-Nkx2.5/GATA4 also may contribute to PFOA-induced 
developmental cardiotoxicity. Moreover, the PPARα and BMP2 pathways seemed 
interconnected, as indicated by the effect of WY 14,643 on pSMAD1/5 concentrations. Figure 6 
contains a summary of this study. Studies are ongoing with ex vivo primary cardiomyocyte 
cultures to further investigate the potential mechanisms of developmental cardiotoxicity 
associated with in ovo PFOA exposure. 
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Figure 3.1 Histological assessment of hearts from embryonic day 19 (ED19) chicken embryos 
exposed to WY 14,643 in ovo. Fertile chicken eggs were injected with 0, 5, or 25 mg of 
WY14,643/kg of egg weight and incubated until ED19. Hearts were sectioned at 6 µ and stained 
with hematoxylin and eosin or for myosin. A: Illustration of a dense layer of myosin staining, 
shown between arrows. B: Representative section of a heart from an ED19 chicken embryo 
exposed to vehicle. Scale bar represents 1000 µm. C: Representative section of a heart from an 
ED19 chicken embryo exposed to 2 mg of PFOA/kg of egg weight. Scale bar represents 1000 
µm. D: Representative section of a heart from an ED19 chicken embryo exposed to 25 mg of 
WY 14,643/kg of egg weight. Scale bar represents 1000 µm. E: Quantification of mean right 
ventricular wall thickness. F: Quantification of mean thickness of a dense layer of myosin 
staining in the right ventricular wall.  Error bars represent standard deviation, SD. 
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Figure 3.2 Results of quantitative real-time PCR for liver-fatty acid binding protein (L-FABP), 
an indicator of PPARα activation. Fertile chicken eggs were injected 0, 5, or 25 mg of WY 
14,643/kg of egg weight or 2 mg of PFOA /kg of egg weight and incubated until hatch. Error 
bars represent standard deviation, SD. Mean expression of L-FABP in liver was assessed with 
PCR (N=5-6). *Statistically different from vehicle controls (P < 0.05). 
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Figure 3.3 Western blot quantification of pSMAD1/5 in four-day-old (ED4) chicken embryos 
exposed to PFOA or WY 14,643; error bars represent standard deviation, SD. (A) pSMAD1/5 in 
the cytoplasmic portion of PFOA-exposed embryos (N=9-10). (B) pSMAD1/5 in the nuclear 
portion of PFOA-exposed embryos (N=9-10) (C) pSMAD1/5 in the cytoplasmic portion of WY 
14,643-exposed embryos (N=6-10). (D) pSMAD1/5 in the nuclear portion of WY 14,643-
exposed embryos (N=6-11). (E) Representative blot of pSMAD1/5 from PFOA-exposed 
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embryos. The upper panel is the cytoplasmic portion and the lower panel is the nuclear portion. 
(F) Representative blot of pSMAD1/5 from WY 14,643-exposed embryos. The upper panel is 
the cytoplasmic portion and the lower panel is the nuclear portion. *Statistically different from 
vehicle controls (P < 0.05). 
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Figure 3.4 Results of quantitative real-time PCR for pathways critical in early heart 
development. Fertile chicken eggs were injected with 0, 0.5, 1, or 2 mg of PFOA/kg of egg 
weight and incubated for four (ED4) or six (ED6) days. Error bars represent standard deviation; 
SD. (A) BMP2 gene expression in ED4 whole embryos (N=6-9). (B) Nkx2.5 gene expression in 
hearts from ED6 embryos (N=8). (C) GATA4 gene expression in hearts from ED6 embryos 
(N=6-8). *Statistically different from vehicle controls (P < 0.05).
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Figure 3.5 Western blot quantification of Nkx2.5 and pGATA4 in hearts from six-day-old (ED6) 
chicken embryos exposed to PFOA or WY 14,643. Error bars represent standard deviation, SD. 
(A) Nkx2.5 (N=6-10). (B) pGATA4 (N=6-8). (C) Representative blot of Nkx2.5 and pGATA4. 
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Figure 3.6 Summary of the study. Dark shaded squares represent the pathways affected by 
PFOA exposure; light shaded squares represent the pathways affected by WY 14,643 exposure. 
Closed arrows represent conclusions from published data (DeWitt et al. 2009; Luo et al. 2009; 
Yamane et al. 2003; Kirby 2002; Barron et al. 2000; McCulley et al. 2012; Harvey et al. 2002 
and Pu et al. 2004); open arrows represent conclusions from the current study. 
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 Table 3.1 General developmental toxicity parameters in 19-day-old chicken embryos and 
hatchling chickens exposed to WY 14,643 during development. 
 
 
ED19 Embryos Hatchlings 
 
Vehicle 5 mg/kg 25 mg/kg Vehicle 5 mg/kg 25 mg/kg 
Yolk-free body 
weight (g) 
27.78±1.33 28.44±2.40 27.22±2.25 32.44±2.35 30.93±2.15 30.52±2.80 
Absolute heart 
weight (g) 
0.20±0.014 0.20±0.023 0.20±0.022 0.28±0.034 0.30±0.042 0.31±0.034 
Relative heart 
weight 
0.0072±0.00068 0.0070±0.0009 0.0074±0.00045 0.0087±0.00090 0.0096±0.00110 0.010±0.00070* 
Relative liver 
weight 
0.014±0.0024 0.013±0.0014 0.015±0.0017 0.022±0.0026 0.024±0.0029 0.025±0.0016 
Mortality 20.0% 30.0% 20.0% 41.7% 25.0% 33.3% 
Hatchability - - - 77.8% 100.0% 100.0% 
Note. Weight values are means ± standard deviation. Injection concentration was based on kg of 
egg weight. For organ weight, N = 7-8/dose group for ED19 embryos and 7-9/dose group for 
hatchlings. For mortality and hatchability, N = 11/dose group for ED19 embryos and 12/dose 
group for hatchlings. Relative heart and liver weight = absolute weight of each organ corrected 
by yolk-free body weight. Hatchability was calculated as the number of successfully hatched 
chickens adjusted by the number of chicken embryos that were alive at ED20.  *Statistically 
different from vehicle control (P < 0.05). 
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 Table 3.2 Mean echocardiography results of structural parameters measured in hearts of 
hatchling chickens exposed to WY 14,643 during development. 
 
 
Value 
Parameter Vehicle 5 mg/kg 25 mg/kg 
Left ventricular wall posterior dimension at 
diastole (mm) 
0.506±0.009 0.615±0.027* 0.996±0.031* 
Left ventricular wall posterior dimension 
systole (mm) 
1.188±0.006 1.436±0.019* 1.712±0.168* 
Left ventricular volume at diastole (ul) 70.055±6.879 59.902±6.322* 44.796±4.175* 
Left ventricular volume at systole (ul) 15.136±1.862 8.203±1.873* 4.196±1.322* 
Left ventricule mass (mg) 93.3±5.0 115.6±6.3* 134.8±4.0* 
Heart rate (bpm) 246.0±18.1 364.0±18.4* 393.0±7.9* 
Stroke volume (ul) 54.919±8.332 51.699±6.887 40.600±5.033* 
Cardiac output (ml/min) 192.2±19.0 313.6±15.9* 355.4±16.5* 
Ejection fraction (%) 78.1±4.3 86.1±3.6* 90.4±3.7* 
Fractional shortening (%) 58.6±1.2 56.8±2.6 62.2±4.1* 
Note. Values are means ± standard deviation. Injection concentration was based on kg of egg 
weight. N = 7–9/dose group. *Statistically different from vehicle controls (P < 0.05). 
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CHAPTER 4 PFOA-INDUCED TOXICITY IN PRIMARY CULTURES OF CHICKEN 
EMBRYO CARDIOMYOCYTES (WILL BE SUBMITTED TO ARCHIVES OF 
ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY) 
 
Abstract 
 Perfluorooctanoic acid (PFOA) is a widespread environmental contaminant that 
induces developmental cardiotoxicity in late stage chicken embryos and hatchling chickens. To 
investigate mechanism(s) of cardiotoxicity, primary cultures of cardiomyocytes were prepared 
from ten-day-old chicken embryos that were A) pre-exposed to vehicle or 2 mg of PFOA/kg of 
egg weight in ovo or B) incubated with PFOA in vitro at concentrations ranging from 0 to 100 
µg/ml in medium for one or 36 hours. . When viability was assessed, survival of cardiomyocytes 
prepared from pre-exposed embryos did not differ from vehicle controls, even under conditions 
of serum starvation designed to challenge the cells. One hour of exposure to 100 µg/ml of PFOA 
in vitro and 36 hours of exposure to 75 and 100 µg/ml PFOA in vitro decreased viability. When 
contractility was evaluated, cardiomyocytes cultured from pre-exposed embryos exhibited 
decreases in time to maximum departure velocity and cell length at peak contraction, whereas 
cardiomyocytes exposed in vitro exhibited a reduction in the 50% relaxation time at a 
concentration of 1 µg/ml relative to vehicle controls. Reactive oxygen species (ROS) generation, 
which was evaluated only in cultures exposed to PFOA in vitro, was significantly induced 
following incubation with 50 µg/ml of PFOA for one hour. These data indicate that while in vitro 
exposure to relatively high concentrations of PFOA can induce cytotoxicity and ROS, 
developmental cardiotoxicity observed in ovo is not likely mediated via PFOA-induced overt 
cytotoxicity, but by interference of upstream signals that regulate early heart development. 
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4.1 Introduction 
Perfluorooctanoic acid (PFOA) is a fluorinated compound that belongs to the perfluoroalkyl 
acid (PFAA) family of chemicals. Production of PFOA began in the 1950s and it is primarily 
used as a polymerization aid in the manufacture of fluorinated polymers and elastomers for 
myriad industrial and consumer products. PFOA is persistent in environmental media 
(Vaalgamaa et al. 2011) and is now detected in biota as well as the serum of the general human 
population. Between 2009 and 2010 in the US, the median serum concentration in the general 
human population was 3.2 ng/ml (CDC 2012). However, it is estimated that exposure levels 
could be much higher in areas with contaminated media. For example, Shin et al. (2011) reported 
a median serum value of 24.3 ng/ml in residents from an area of high contamination in West 
Virginia and Ohio, US. Hoffman et al. (2011) reported a median serum value of 75.7 ng/ml in 
communities surrounding a fluoropolymer production facility. The highest serum levels were 
observed in occupationally-exposed workers; Olsen et al. (2007) reported up to 5100 ng/ml 
serum. Due to increasing reports of adverse health effects, the US Environmental Protection 
Agency (USEPA) worked with eight major manufacturers of PFOA to establish a stewardship 
program that will phase out PFOA in emissions and products in the US by 2015 (USEPA 2013). 
However, the stability of PFOA in the environment and its long half-life in humans will likely 
mean that exposure will continue for a considerable time.  
There is epidemiological evidence that PFOA affects human development. Stein et al. 
(2009) reported an association of PFOA serum concentrations with preeclampsia and birth 
defects. Frisbee et al. (2010) reported association between PFOA exposure and elevated serum 
cholesterol levels and uric acid levels in children and adolescents. A recent study correlates 
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PFOA exposure to decreased vaccination responses in children between five and seven years old 
living in the Faroe Islands (Grandjean et al. 2012).  
In animal models, PFOA is known to induce hepatic, pancreatic, and testicular cancers 
(Biegel et al. 2001), endocrine disruption (Olsen et al. 1998), immunotoxicity (DeWitt et al. 
2008), and developmental toxicity, including increased mortality and retarded development 
(Wolf et al. 1997). The mechanisms underlying high mortality and retarded development 
following developmental exposure to PFOA have not yet been elucidated.  
In our previous study (Jiang et al. 2012), we observed developmental cardiotoxicity in a 
chicken model. Following developmental exposure to PFOA, chicken embryo hearts exhibited 
morphological changes, including thinning of the right ventricular wall and thinning of a layer of 
dense myosin staining within the right ventricular wall. Hearts from developmentally-exposed 
hatchling chickens had increased left ventricular dimension and altered left ventricular function. 
In this study, we further explored developmental cardiotoxicity associated with PFOA exposure 
by evaluating changes in primary cardiomyocytes cultured from embryonic day 10 chickens. 
Viability, contractility, and reactive oxygen species (ROS) generation were evaluated to assess 
PFOA-induced cytotoxicity. 
 
4.2 Materials and methods 
4.2.1 Animals 
Fertile chicken (Gallus gallus) eggs were purchased from the North Carolina State 
University Poultry Research Center (Raleigh, NC). Eggs were cleaned with 20% povidone 
iodine, weighed, given ID numbers, and evenly distributed by weight among doses. The eggs 
used for air cell injections were candled to outline air cells in pencil on shells. 
 78 
 
4.2.2 Chemicals 
Sunflower oil was purchased from Spectrum Organic Products, LLC (Boulder, CO). 
PFOA and other chemicals (if not otherwise mentioned) were purchased from Sigma-Aldrich 
(St. Louis, MO). 
4.2.3 Egg injection, incubation and sample collection 
For primary cardiomyocyte cultures prepared from pre-exposed embryos, egg injection and 
incubation were carried out as described previously (Jiang et al. 2012). Briefly, PFOA was 
suspended in sunflower oil and vortexed before injection into each egg. Stock solutions were 
prepared so that 0.1 µl of solution per gram of egg resulted in the appropriate mg/kg 
concentration. Dose selection for PFOA was based on observations by O’Brien et al. (2009) and 
data from our previous work (Jiang et al. 2012). O’Brien et al. reported that up to 10 mg/kg of a 
PFOA injection does not affect pipping success; in our previous studies, injection of 2 mg of 
PFOA/kg of egg weight resulted in a serum concentration of 5670 ng/ml in hatchlings, a level 
comparable to occupationally-exposed humans.   
Uninjected eggs (for preparation of primary cardiomyocyte cultures exposed in vitro) and 
injected eggs (for preparation of pre-exposed primary cardiomocyte cultures) were incubated for 
ten days in a Lyon Roll-X incubator (Chula Vista, CA) set at 99.5–100ºF dry bulb and 87–88º F 
wet bulb. Eggs were incubated in separate batches to avoid cross-contamination and the 
incubator was cleaned after each round of incubation. At ED10, eggs were removed from the 
incubator and opened under sterile conditions in a cell culture hood. Embryos were removed 
from eggs and hearts were removed and dissected, and treated as described in the following 
section. All procedures were approved by the East Carolina University Institutional Animal Care 
and Use Committee. 
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4.2.4 Primary cardiomyocyte cultures 
The primary cardiomyocyte culture procedure was as described in Jones et al. (2009) 
with minor modifications. Briefly, hearts were rinsed in cardiomyocyte medium (54% Hanks 
balanced salt solution (HBSS), 40% medium M199, 6% fetal bovine serum, 100 unit/ml 
penicillin, 0.1 mg/ml streptomycin, and 0.03mg/ml 5-bromo-2-deoxyouridine (BrdU)). A pre- 
digestion was carried out with digestion buffer (0.5 mg/ml trypsin and 0.05 mg/ml DNAse I 
(Roche, Mannheim, Germany) in HBSS) in a shaking incubator at 37°C for ten minutes. The 
resulting suspension was discarded and five to seven more digestion cycles were performed in 
digestion buffer in a shaking incubator at 37°C for seven minutes each cycle. The same volume 
of ice cold trypsin inhibitor buffer (10 mg/ml albumin, 20% fetal bovine serum, 80% HBSS with 
antibiotics) was then mixed with the final suspension and filtered through a filtration apparatus 
(BioDesign Inc. of New York, NY). The suspension was centrifuged, washed, and resuspended 
in cardiomyocyte medium at 1:32 dilution (mg/µl). The stock cell suspension was plated in 96-
well plates at 70-80% coverage (33.3 µl stock/cm2 , 1:20 concentration in medium) for viability 
and ROS detection assays, or plated in 6-well plates at 30-50% coverage (10.4 µl stock/cm2, 
1:20 concentration in medium) for contractility assays. After 24 hours, the cells were ready for 
treatment and/or evaluation as by that time they had adhered to the plate and exhibited 
spontaneous beating (at 70-80% coverage) that was observable under an inverted microscope. 
Figure 4.1 shows a representative image of primary cardiomyocytes after 72h of incubation.  
4.2.4.1 Primary cardiomyocyte cultures from pre-exposed embryos 
To determine developmental effects of PFOA on cardiomyocytes, groups of eggs were 
injected with either vehicle or 2 mg of PFOA/kg of egg weight prior to incubation. Freshly 
isolated cells from injected eggs were plated in 96-well culture plates, as described above, in 
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triplicate. After 24 hours, attached cardiomyocytes were serum-starved to evaluate the effects of 
stress on cell survival. Cells were treated with normal medium, low serum medium (1.8% 
serum), serum free medium (0% serum), or no medium as a positive control (HBSS with 
antibiotics and BrdU). Cells were cultured for 0, 12, or 24 hours and viability was assessed with 
a Celltiter 96 AQueous One Solution Cell Proliferation Assay (MTS) viability kit (Promega, 
Madison, WI), using the manufacturer’s protocol. To evaluate contractility, a separate group of 
cells isolated from ED10 embryos pre-exposed to PFOA in ovo were plated into 6-well culture 
plates containing 25 mm round glass coverslips and cardiomyocyte medium and incubated. After 
24 hours, the glass coverslips were removed from the plates, rinsed in Tyrode buffer (sodium 
chloride 137 mM, potassium chloride 5.4 mM, calcium chloride 1.2 mM, magnesium chloride 
1.5 mM, HEPES 10 mM, and glucose 10mM), and installed on a stimulation chamber (IonOptix, 
Milton, MA) in an IonOptix system (Milton, MA). An IonOptix MyoPacer Cell Stimulator was 
used to stimulate the cells at 20V, 1HZ, at room temperature. Departure velocity, time to 
departure velocity, time to 50% peak contraction, time to 50% relaxation, cell length at 
maximum contraction, and cell shortening percentage at peak contraction were measured.  
4.2.4.2 Primary cardiomyocyte cultures exposed to PFOA in vitro 
To determine direct effects of PFOA on cardiomyocytes, three separate cultures of primary 
cardiomyocytes were prepared from ED10 embryos collected from uninjected eggs. For 
evaluating viability, cultures were incubated for 24 hours and then exposed to vehicle 
(cardiomyocyte medium with 0.1% DMSO) or 0.1, 1, 10, 50, 75, or 100 µg/ml of PFOA in 
cardiomyocyte medium with 0.1% DMSO for one or 36 hours. At least three independent 
isolations were used for each experimental group. Viability was assessed with a Celltiter 96 
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AQueous One Solution Cell Proliferation Assay (MTS) (Promega, Madison, WI), using the 
manufacturer’s protocol. 
To evaluate contractility, cultures were plated into 6-well culture plates containing 25 mm 
round glass coverslips and cardiomyocyte medium and incubated. After 24-26 hours, cultures 
were exposed to vehicle (cardiomyocyte medium with 0.1% DMSO) or 0.1, 1, 10, 50, 75, or 100 
µg/ml of PFOA in cardiomyocyte medium with 0.1% DMSO for one hour. The glass coverslips 
were then removed from the plates and contractility was evaluated with IonOptix instruments as 
described above. 
To evaluate ROS, cultures were incubated for 24 hours and then 2',7'-dichlorofluorescein 
(DCF; Life technologies, Grand Island, NY) stock solution made with Dulbecco's phosphate-
buffered saline (DPBS) and DMSO was added for a final concentration of 20 µM in the medium. 
After incubating cultures for 30 minutes in DCF, cultures were exposed to vehicle 
(cardiomyocyte medium with 0.1% DMSO) or 0.1, 1, 10, or 50 µg/ml of PFOA in 
cardiomyocyte medium with 0.1% DMSO for one more hour. The medium was removed, cells 
were washed twice in PBS, and plates were read at excitation 495nm/emission 525nm (Tecan 
Infinite M200Pro, Research Triangle Park, NC) to detect ROS. Values were normalized to the 
vehicle treated group for fold changes. 
4.2.5 Statistical analysis 
Data are presented as mean ± standard deviation (SD) for both cell viability and ROS. 
Contractility data are presented as mean ± standard error of the mean (SEM). Statistical analyses 
were performed with the SAS JMP System (SAS Institute, Cary, NC). One-way analysis of 
variance (ANOVA) was used to determine dose-dependent effects for all in vitro endpoints and 
for contractility results of the cultures prepared from pre-exposed embryos. When ANOVA 
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results indicated statistically significant dose effects, individual post hoc comparisons were made 
with a two-tailed t-test. Two-way ANOVA was used to determine dose and serum concentration 
effects on ex vivo viability. When ANOVA results indicated statistically significant main effects 
of dose and serum concentration without interactions between dose and serum concentration, 
individual post hoc comparisons were made with a two-tailed t-test. Statistical significance was 
determined when P-values were less than 0.05. 
 
4.3 Results 
4.3.1 Primary cardiomyocyte cultures from pre-exposed embryos  
Two-way ANOVA indicated that serum starvation impacted cell viability in 
cardiomyoctyes from both control and PFOA-exposed embryos. PFOA exposure itself did not 
impact cell viability (Figure 4.2). Among the contractility parameters measured with the 
IonOptix System, the time to departure velocity was decreased by 40.9% in cardiomyocytes from 
PFOA-exposed embryos relative to controls (Figure 4.3b). The cell length at maximum 
contraction was decreased by 23.7% in cardiomyocytes from PFOA-exposed embryos relative to 
controls (Figure 4.3e). No statistical differences were detected for other parameters (Figures 
4.3a, c, d and f). 
4.3.2 Primary cardiomyocyte cultures exposed to PFOA in vitro 
Following one hour of exposure to 100 µg/ml of PFOA, cell viability was decreased by 
72.4% (Figure 4.4a). After 36 hours of exposure to75 or 100 µg/ml of PFOA in cardiomyocyte 
medium, viability decreased by 26.4% and 69.4%, respectively (Figure 4.4b). Among the 
contractility parameters measured with the IonOptix System, the time to 50% relaxation was 
increased by 38.2% following one hour of exposure to 1 µg/ml of PFOA in cardiomyocyte 
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medium (Figure 4.5d). No significant differences were found for other parameters measured 
(Figure 4.5a, b, c, e and f). One hour of exposure to 50 µg/ml of PFOA in cardiomyocyte 
medium increased ROS generation in primary cardiomyocytes by 316.8% (Figure 4.6). 
 
4.4 Discussion 
In our previous study (Jiang et al. 2012), developmental cardiotoxicity was observed in 
chicken embryos and hatchling chickens exposed to PFOA via air cell injection prior to 
incubation. Hearts of PFOA-exposed ED19 embryos had thinner right ventricular walls relative 
to control embryos. When hearts of the hatchling chickens were evaluated with 
echocardiography, left ventricle hypertrophy and elevated functional parameters were observed 
in exposed hatchlings relative to control hatchlings. We undertook the current study to explore 
potential cellular mechanisms of PFOA-induced developmental cardiotoxicity. Our experiments 
were designed to assess whether the developmental cardiotoxicity was a result of direct 
cytotoxicity of PFOA to cardiomyocytes or a result of effects on upstream developmental 
processes. The concentration of PFOA injected into chicken eggs prior to incubation was 2 
mg/kg of egg weight, the highest dose that was injected in our previous study for characterization 
of PFOA-induced developmental cardiotoxicity (Jiang et al. 2012). This dose is approximately 2 
µg/ml if perfect equilibrium is achieved within eggs. The average PFOA serum concentration in 
hatchling chickens from eggs injected with 2 mg/kg prior to incubation was 5.67 µg/ml (Jiang et 
al. 2012). Although the precise dose at a specific time point during development was not 
determined, the actual exposure to the developing embryos was likely between 2 µg/ml and 5.67 
µg/ml. The PFOA concentrations used in the in vitro experiments were 0.1, 1, 10, 50, 75 and 100 
µg/ml. Slotkin et al. (2008) demonstrated that at concentrations below100 µg/ml of PFOA, cell 
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damage in PC-12 cells was not detectable. Our range of concentrations for the in vitro 
experiments therefore included low concentrations (0.1 µg/ml), a concentration close to the ex 
vivo dose (1 µg/ml), and higher concentrations to cover a wide range. A concentration of 50 
µg/ml was used as the highest dose for the contractility and ROS generation assays to ensure that 
observed affects were not attributable to overt cytotoxicity, as evaluation of viability indicated 
that 75 µg/ml and 100 µg/ml induced cell death. 
 PFOA did not markedly affect the yield of cells by weight per embryo heart (data not 
shown) or reduce viability of primary cardiomyocytes prepared from pre-exposed embryos, 
either under normal conditions or conditions of serum starvation. The serum starvation 
conditions were applied to investigate the ability of cardiomyocytes developmentally exposed to 
PFOA to survive under stressful conditions. This particular challenge was chosen as toxicity of 
PFOA is associated with activation of the peroxisome proliferator activated receptor alpha 
(PPAR ), a transcription factor that regulates fatty acid and other forms of energy metabolism 
(Montanez et al. 2012). Our results demonstrated that pre-exposure of embryos to 2 mg/kg of 
PFOA did not significantly impact the ability of the cardiomyocytes to survive an energy 
challenge. Alternatively, when primary cardiomyocytes were exposed to PFOA in vitro, viability 
was decreased, but only at the highest concentrations (75 and 100 µg/ml). These concentrations 
far exceed the dose applied to the pre-exposed cardiomyocytes and our previous in ovo study 
(Jiang et al. 2012). While extreme conditions associated with very high exposure levels may 
induce cell death, overt cytotoxicity is likely not a key mechanism of PFOA-induced 
developmental cardiotoxicity. These results suggest that decreased cell viability or a potential 
deficiency in processes associated with energy metabolism likely do not significantly contribute 
to cardiotoxicity arising from developmental PFOA exposure. 
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Assessing contractility of cardiomyocytes provided information about the ability of 
cardiomyocytes from ten-day-old chicken embryos to function normally. At ED10, 
cardiomyocytes are well developed, capable of spontaneous beating in culture (Bézie et al. 1996) 
and respond to an external pacer. In the primary cardiomyocyte cultures from pre-exposed 
embryos, the time to reach maximum departure velocity (the maximal rate of cell edge position 
change during the contraction) was significantly decreased. This finding is consistent with our 
previous echocardiography data that recorded an increased heart rate in hatchling chickens 
exposed to PFOA throughout embryonic development (Jiang et al. 2012). While the cell 
shortening percentage at maximum contraction, which is equivalent to fractional shortening at 
the cellular level, did not differ significantly between vehicle-exposed and PFOA-exposed cells, 
the cell length at peak contraction was decreased. This finding is related to the increased ejection 
fraction, fractional shortening, and decreased left ventricular volume observed in hatchling 
chickens exposed to PFOA throughout embryonic development (Jiang et al. 2012). As an 
optimized cell shape is required for normal contractility (Kuo et al. 2012), an abnormal cell 
length could indicate that structural compensation is necessary to maintain the same degree of 
cardiac output. Long-term compensation therefore could eventually lead to cardiac remodeling 
and heart failure (Calvé et al. 2012). These data lead us to hypothesize that PFOA affects 
cardiomyocyte development via interference of early stage cardiomyocyte differentiation and/or 
proliferation.  
Cells that were directly exposed to PFOA in vitro for one hour did not show similar 
alterations. The functional parameter that was significantly changed was an increase in time to 
50% relaxation following 1 µg/ml of PFOA exposure. Changes to this parameter indicate slower 
repolarlization and thus a potentially longer QT interval, a common indicator of cardiotoxicity 
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typically induced by drugs (Recanatini et al. 2005). Additionally, a slower repolarization will 
potentially lead to a slower heart rate, which is contradictory to the increase in heart rate that we 
observed in PFOA-exposed hatchling chickens (Jiang et al. 2012). Although 1 µg/ml of PFOA in 
vitro did not statistically decrease cell viability, it is possible that this concentration of PFOA 
was sufficient to impact the ability of the cardiomyocytes to function optimally. Interestingly, 
this dose is close to the PFOA serum levels measured in hatchling chickens exposed in ovo 
(Jiang et al. 2012). The precise reason for a lack of detectable effects at the 10 and 50 µg/ml 
concentrations is unknown. The relatively large variability associated with evaluating 
contractility in the cardiomyocytes might have prevented the changes from being detected. While 
the change in time to 50% relaxation indicates that PFOA can impact cardiomyocytes exposed in 
vitro, it does not seem to be a mechanism for the developmental cardiotoxicity that we observed 
in ovo in Jiang et al. (2012) as this functional change is somewhat inconsistent with the in ovo 
results. The animals exposed in ovo had a higher heart rate and a slower relaxation will likely 
lead to slower heart rate. Our mechanistic work (Jiang et al. under review) indicated that PPARα 
is partially involved in PFOA-induced developmental cardiotoxicity in ovo as animals exposed 
to a PPARα agonist had similar functional, but not histological changes to the heart. We 
therefore speculate that PPARα agonism also is not mediating this particular effect as PPAR  
and PPAR  activation does not induce a long QT interval in human patients (Sturm et al. 2012).  
In summary, the primary cardiomyocytes isolated from hearts ED10 chicken embryos pre-
exposed to 2 mg of PFOA/kg of egg weight had functional and morphological changes that were 
consistent with and support our previous in ovo findings. The differences between effects 
observed in primary cardiomyocytes pre-exposed to PFOA or directly exposed in vitro suggest 
that mechanisms of developmental cardiotoxicity induced by PFOA are mediated via upstream 
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interference of early differentiation and/or proliferation of cardiomyocytes, not via overt 
cytotoxicity of PFOA to cardiomyocytes.  
ROS generation is a main mechanism of direct cytotoxicity. Cardiomyocytes are known to 
be vulnerable to ROS generation, which is the molecular mechanism of cardiotoxicants such as 
doxorubicin (Ludke et al. 2012). PFOA has been reported to induce ROS generation (Eriksen et 
al. 2010); however, we were unable to uncover published results on ROS generation in 
cardiomyocytes following PFOA exposure. Cells that were exposed to PFOA in vitro for one 
hour after a 24-hour incubation had a significant increase in ROS generation, but only at the 
highest concentration tested (50 µg/ml). This suggests that ROS generation could contribute to 
developmental cardiotoxicity but only at high doses. Therefore, ROS generation in 
cardiomyocytes does not likely contribute substantially to the cardiotoxicity observed in 
hatchling chickens exposed to PFOA throughout embryonic development (Jiang et al. 2012).  
 
4.5 Conclusion 
In this study, decreased cell viability and increased ROS generation were observed in 
primary cardiomyocytes that were directly exposed to PFOA in vitro, but only at high 
concentrations. Therefore, overt cytotoxicity induced by PFOA is unlikely unless exposure levels 
are very high, implying that this mechanism is not relevant to human health except at very high 
exposures. For example, Olsen et al. (2007) reported occupational exposures that resulted in 
PFOA serum concentration of 5100 ng/ml, which is approximately equivalent to 5.1 µg/ml in 
vitro. Direct exposure of cardiomyocytes to PFOA in vitro also increased relaxation time for 
contraction, suggesting that PFOA may induce a long QT interval. Additional work is necessary 
to determine if this one functional change is relevant to public health.  
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Altered morphology and function were observed in cardiomyocytes isolated from pre-
exposed embryos and this positive chronotropic effect is consistent with our previous in ovo 
findings. Directly-exposed cardiomyocytes did not have similar alterations after one hour of in 
vitro exposure to PFOA, suggesting that PFOA induces developmental cardiotoxicity in early 
stages of development, not through direct contact with developed cardiomycoytes. These 
morphological and functional alterations occur at relatively low doses that are comparable with 
concentrations observed in the general human population. Further work is necessary to further 
elucidate the molecular mechanisms of PFOA interference with early heart development.  
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Figure 4.1 Representative image of primary cardiomyocyte isolated from ED10 chicken embryo 
hearts incubated for approximately 72 hours. 
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Figure 4.2 Cell viability of primary cardiomyocytes exposed to vehicle or 2 mg of PFOA/kg of 
egg weight prior to incubation. Air-cell injected fertile chicken eggs were incubated until 
embryonic day ten and primary cardiomyocytes were isolated from embryos. Three independent 
isolations of primary cardiomyocytes were used for both exposure groups. Following 24 hours of 
incubation, cardiomyocytes were exposed to normal medium, low serum medium, serum-free 
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medium or medium-free conditions for 0, 12, or 24 hours. (a) Viability of primary 
cardiomyocytes subjected to brief serum starvation (0 hours) (N=3-4). (b) Viability of primary 
cardiomyocyte subjected to serum starvation for 12 hours (N=3-4). (c) Viability of primary 
cardiomyocyte subjected to serum starvation for 24 hours (N=3-4). Data are presented as mean ± 
SD. 
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Figure 4.3 Contractility of primary cardiomyocytes exposed to vehicle or 2 mg of PFOA/kg of 
egg weight prior to incubation. Three independent isolations of primary cardiomyocytes were 
used for both exposure groups. Air-cell injected fertile chicken eggs were incubated until 
embryonic day ten; primary cardiomyocytes were isolated from embryos and incubated for 24 
hours. (a) Departure velocity (N=30 for vehicle, 29 for PFOA-exposed). (b) Time to departure 
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velocity (N=30 for vehicle, 29 for PFOA-exposed).  (c) Time to 50% peak contraction (N=30 for 
vehicle, 29 for PFOA-exposed). (d) Time to 50% relaxation (N=29 for vehicle, 28 for PFOA -
exposed). (e) Cell length at maximum contraction (N=30 for vehicle, 29 for PFOA-exposed). (f) 
Cell shortening percentage at maximum contraction (N=30 for vehicle, 29 for PFOA-exposed).  
Data are presented as mean ± SEM. * Denotes statistical difference from vehicle group (P<0.05). 
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Figure 4.4 Cell viability of primary cardiomyocytes exposed to PFOA in vitro. Unexposed 
fertile chicken eggs were incubated until embryonic day ten and primary cardiomyocytes were 
isolated from embryos. Three independent isolations of primary cardiomyocytes were used. 
Following 24 hours of incubation, cardiomyocytes were exposed to 0, 0.1, 1, 10, 50, 75 or 100 
µg/ml PFOA in 0.1% DMSO and incubated for one or 36 hours. Doxorubicin applied at 0.5 uM 
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was included as positive control in the 36-hour exposure group. (a) Viability of primary 
cardiomyocytes exposed to PFOA for one hour (N=4-6). (b) Viability of primary cardiomyocytes 
exposed to PFOA for 36 hours (N=4-6).  Data are presented as mean ± SD. * Denotes statistical 
difference from vehicle group (P<0.05).  
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Figure 4.5 Contractility of primary cardiomyocytes exposed to PFOA in vitro. Unexposed fertile 
chicken eggs were incubated until embryonic day ten and primary cardiomyocytes were isolated 
from embryos. Three independent isolations of primary cardiomyocytes were used. Following 24 
hours of incubation, cardiomyocytes were exposed to 0, 0.1, 1, 10 or 50 µg/ml PFOA in 0.1% 
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DMSO and incubated for one hour. (a) Departure velocity (N=9-16). (b) Time to departure 
velocity (N=9-16). (c) Time to 50% peak contraction (N=9-16). (d) Time to 50% relaxation 
(N=9-16). (e) Cell length at maximum contraction (N=9-16). (f) Cell shortening percentage at 
maximum contraction (N=9-16). Data are presented as mean ± SEM. * Denotes statistical 
difference from vehicle group (P<0.05).  
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Figure 4.6 Reactive oxygen species (ROS) generation in primary cardiomyocytes exposed to 
PFOA in vitro. Unexposed fertile chicken eggs were incubated until embryonic day ten and 
primary cardiomyocytes were isolated from embryos. Following 24 hours of incubation, 
cardiomyocytes were incubated with 20 µM 2',7'-dichlorofluorescein (DCF) for 30 minutes and 
then incubated with 0, 0.1, 1, 10, or 50 µg/ml PFOA in 0.1% DMSO for one hour. Fold change 
relative to the vehicle group was assessed (N=3). Data are presented as mean ± SD. * Denotes 
statistical difference from vehicle group (P<0.05).  
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CHAPTER 5 CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Conclusions 
During this dissertation work, developmental cardiotoxicity induced by PFOA in a 
chicken embryo model was identified and studied. The detailed results are reported in three 
manuscripts (Chapters 3-5). The first manuscript (Chapter 3) focused on the morphological and 
functional changes induced by PFOA in hearts of late stage chicken embryos and hatchling 
chickens and was published in Toxicology; the second manuscript (Chapter 4) focused on 
molecular mechanisms of PFOA-induced developmental cardiotoxicity and has been accepted 
for publication in the Journal of Toxicology and Environmental Health Part A; the third 
manuscript (Chapter 5) focused on cellular mechanisms of PFOA-induced developmental 
cardiotoxicity and will be submitted to the Archives of Environmental Contamination and 
Toxicology. 
In the studies that were summarized in my first manuscript, PFOA-induced 
developmental cardiotoxicity was first identified with a novel histological endpoint: right 
ventricular wall thickness and the thickness of a dense layer of myosin staining within the right 
ventricular wall. This histological endpoint was then confirmed with echocardiography, which 
measured associated morphological and functional alterations. These endpoints indicated that in 
ovo PFOA exposure altered heart development and that the left ventricle behaved like an early 
hypertensive heart in the compensation stage. This was a completely new endpoint identified for 
an organism exposed to PFOA.  
In my second manuscript, the mechanisms of toxicity for PFOA-induced developmental 
cardiotoxicity were assessed. WY 14,643, a known agonist of PPARα, failed to mimic 
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histological changes after in ovo exposure as no difference in the thickness of the right 
ventricular wall or in the thickness of the dense layer of myosin staining were observed. In ovo 
WY 14,643 exposure did, however, mimic most of the morphological and functional changes to 
the left ventricle induced by PFOA when assessed with echocardiography, suggesting partial 
involvement of PPARα. Pathways alternative to PFOA agonism were then investigated, 
including inflammatory cytokines and the BMP2 signaling pathway. Following PFOA exposure, 
alterations of BMP2, its second messenger, and downstream target gene expression levels were 
observed in early embryos exposed to PFOA in ovo. These changes suggest that the mechanisms 
of PFOA-induced developmental cardiotoxicity are a combination of PPARα activation and 
interference with the BMP2-SMAD-Nkx2.5/GATA4 pathway.  
In the third manuscript, the mechanisms of PFOA-induced cardiotoxicity were further 
investigated with primary cardiomyocyte culture model. Primary cardiomyocytes were exposed 
to PFOA via two methods: in vitro (cells were isolated from hearts of unexposed ED10 embryos 
and were then exposed to PFOA in medium) and pre-exposed (cells were isolated from hearts of 
ED10 embryos exposed to PFOA in ovo, an exposure scenario identical to the in vivo tests). 
When viability of cells exposed to PFOA in vitro was assessed, direct exposure of cells to PFOA 
induced cytotoxicity only at high doses (75 and 100 µg/ml). When viability of cells pre-exposed 
to PFOA in ovo was assessed under a challenge (serum starvation), no cytotoxicity was 
observed. When the contractility of individual cardiomyocytes was examined, cells from hearts 
of pre-exposed embryos had similar morphological and functional changes as hearts from the 
exposed hatchling chickens. Individual cardiomyocytes from cells that were exposed in vitro 
only had a slower relaxation time, which was somewhat inconsistent with observations made on 
hearts of exposed hatchling chickens. Additionally, ROS were only significantly induced 
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following a relatively high concentration of PFOA (50 µg/ml) in medium. These data suggest 
that PFOA induces cardiotoxicity on early upstream signaling pathways in heart development 
and is likely independent of cytotoxicity in cardiomyocytes from direct PFOA contact.  
In summary, the work described in the three chapters together demonstrates that PFOA 
induces developmental cardiotoxicity in an avian model. When developing hearts of chicken 
embryos are exposed to PFOA, cardiotoxicity occurs in the form of morphological and 
functional changes. WY 14,643 experiments indicated that PPARα is involved, but because of 
differences observed in cardiac effects between PFOA-exposed and WY 14,643-exposed 
embryos, PPARα signaling is not the only contributing factor. Molecular studies with early stage 
embryos identified the BMP2-SMAD-Nkx2.5/GATA4 pathway as another contributing factor. 
At the cellular level, while PFOA is capable of inducing overt cytotoxicity and ROS generation 
at high concentrations when applied directly to cardiomyocytes, the interference of PFOA in 
early signaling pathways seems to be responsible for the developmental cardiotoxicity observed 
in vivo, as confirmed with directly-exposed and in ovo exposed primary cardiomyocytes.  
My dissertation work demonstrated that PFOA exposure leads to developmental 
cardiotoxicity in an avian model. The doses used in my studies are higher than exposure levels in 
the general human population: 0.5 mg of PFOA/kg of egg weight, the lowest dose used in the in 
vivo studies, resulted in a serum concentration of 1230.8 ng/ml. The median serum concentration 
of PFOA in the general human population between 2009 and 2010 was 3.2 ng/ml (CDC 2013). 
The relatively large margin of exposure indicates that the developmental cardiotoxicity we 
observed is not likely an immediate threat to public health. However, in relatively highly 
exposed human populations, exposure levels are much higher and closer to the doses in our 
studies. The high values from serum concentration data identified by epidemiological studies 
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(5,100 ng/ml in Olsen et al. 2007 and 17,556.6 ng/ml in Steenland et al. 2009) exceeded the 
values resulting from lower doses administered in our studies. However, no published data are 
currently available on the cardiac health of the offspring of highly-exposed humans. More 
studies are necessary to determine whether the cardiac health of offspring of highly-exposed 
humans is negatively impacted.   
While nominal immediate human health risks are associated with this particular study, 
my dissertation work revealed the potential of developmental cardiotoxicity following exposure 
to an environmental contaminant and united several novel methods for evaluating effects of an 
environmental agent on heart development. These novel methods included evaluation of 
morphology and function in living organisms with echocardiography, histological assessment of 
post-mortem tissues, assessment of morphology and function at the cellular level, and molecular 
biological techniques to evaluate molecular and genetic signaling pathways. My work could 
facilitate the establishment of developmental cardiotoxicity screening test standards.  
 
5.2 Pitfalls and potential improvements 
 In this dissertation work, I identified a novel endpoint of PFOA-induced development 
toxicity and evaluated mechanisms of toxicity. I associated PFOA-induced developmental 
cardiotoxicity with the PPARα pathway and the BMP2-SMAD-Nkx2.5/GATA4 pathway and 
found that early stage interference with cardiomyocyte development rather than overt 
cytotoxicity is likely a mechanism at the cellular level. However, there were some potential 
drawbacks of these experiments and if I had the chance, I would have made a few modifications 
to my experiments.  
 103 
 
 First, as the functional parameters measured by echocardiography in hatchling chickens 
developmentally exposed to PFOA had biphasic responses, additional PFOA doses may 
have helped me to better understand the dose-response. The histological evaluation 
focused on the right ventricle while echocardiography assessments focused on the left 
ventricle; therefore, the relationship between the morphological changes in left and right 
ventricles remains unclear. The big picture of the morphological and functional changes 
could be clearer had I been able to assess the left ventricle histologically and the right 
ventricle with echocardiography. 
 The mechanistic studies on PPARα relied on the selective PPARα agonist WY 14,643. 
While this chemical is generally accepted as a selective PPARα agonist, inclusion of an 
antagonist such as GW6471 to block the PPARα pathway, would have further strengthen 
my conclusions. Similarly, if RNAi gene silencing could have been used in the primary 
cardiomyocyte cultures to knock down PPARα, this would have also strengthened my 
conclusions regarding PPARα signaling. My data suggest that there are interactions 
between the PPARα and the BMP2 signaling pathways, but not all of the experiments 
included both PFOA and WY 14,643 to compare the responses. This limited my 
conclusions about the potential interactions between PPARα and BMP2 signaling. 
Additionally, the mechanistic work based in early chicken embryos could have better 
demonstrated the gene expression changes if I had worked with earlier stage isolated 
hearts rather than embryonic day four embryos and day sixe hearts, especially for genes 
expressed very early in development such as Nkx2.5 and GATA4. The dose-dependent 
differences in mRNA levels might have been more evident in ED4 or earlier stage hearts.   
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5.3 Future directions 
 PFOA is an important industrial and consumer compound that has become a widespread 
environmental contaminant. It has been intensively studied for its potential toxicity but many 
effects remain unknown. In this dissertation, developmental cardiotoxicity was identified in 
hearts of chicken embryos and hatchlings following PFOA exposure. Mechanistic work revealed 
some of the mechanisms of toxicity. However, much still remains to be done in regard to the 
effects of PFOA and related compounds on heart development. 
 First, the long-term health effects of the developmental cardiotoxicity need to be 
determined. Instead of terminating animals within 24 hours of hatching, animals should be kept 
until they reach adulthood. Assessment of morphological and functional parameters should be 
done to determine the persistence of the developmental cardiotoxicity. Discerning whether the 
effects resolve or persist will have important implications for human and environmental health.  
 Second, alternative mechanisms should still be explored. Current work indicated that 
agonsim of PPARα and interference with the BMP2 signaling pathway were potential 
mechanisms of the cardiotoxicity, but additional mechanisms likely exist. First, it is necessary to 
assess additional inflammatory cytokines. mRNA expressions of the cytokines measured in this 
work did not significantly differ. However, only three cytokines were measured and they were 
measured at one specific time point. Embryonic development involves many rapidly changing 
signals; it is possible that these, and other inflammatory cytokines influence the observed effects, 
but at different points in development.  Furthermore, it is possible that the cardiotoxicity arose 
from mechanisms that did not directly impact the heart. For example, if PFOA disrupts 
vasculature resistance or alters the sensitivity of the sympathetic nervous system, elevated 
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circulation pressure could contribute to the effects that were observed in vivo. Additional work is 
necessary to evaluate whether PFOA alters these factors to have an impact on the heart.  
Another potential research direction is the interaction between PFOA and other 
developmental cardiotoxicants, such as 2,3,7,8-tetrachlorodibenzodioxin and polychlorinated 
biphenyls. In the real world, PFOA exposure does not occur by itself and it is capable of 
inducing synergistic effects with other toxicants (Rodea-Palomares et al. 2011). When combined 
with other developmental cardiotoxicants, the toxicity could be additive or multiplicative and 
increase the risk. Additional work on the combined effects of PFOA and other toxicants improve 
understanding on the combined real risk of exposure to environmental contaminants and help 
improve human health.  
 In addition to PFOA, other related perfluorinated compounds such as PFOS, PFHxS, and 
even drugs that act through PPARs, such as fibrates and thiazolidinediones, could potentially 
have similar effects on heart development due to structural or mechanistic similarities. 
Examining these compounds to assess the potential disruption of heart development will provide 
additional insights into the potential mechanisms of toxicity.  
Developmental cardiotoxicity is a relatively understudied area of toxicological research. 
However, the potential risk that it poses to human health should not be underestimated. 
Congenital heart diseases are not the only outcome of developmental cardiotoxicity. My 
speculation is that cardiovascular diseases in adulthood are partially caused by developmental 
cardiotoxicity before birth and/or in early postnatal stages.  
With more work, my ultimate goal regarding developmental cardiotoxicity is to establish 
a universal test set that could be used to screen for potential developmental cardiotoxicity of 
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known and unknown compounds.  This could help improve human health by decreasing both the 
rate of congenital heart disease and adult cardiovascular diseases.  
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